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Abstract
Purpose: Treatment planning accuracy for spine stereotactic body radiation therapy
(SBRT) varies depending on the dose calculation algorithm utilized in the treatment planning
system (TPS). This project compared the end-to-end accuracy between spine SBRT plans
calculated in a convolution-superposition based TPS (TPSCS) and Monte Carlo based TPS (TPSMC)
with radiochromic film measurements. The hypothesis was that TPSMC would calculate the dose
gradient in the critical region between the vertebral body and the spinal cord more accurately than
TPSCS.
Methods: Single-fraction spine SBRT treatments following RTOG 0631 and local
institutional guidelines were planned in TPSCS and TPSMC at five vertebral sites in an
anthropomorphic phantom. The plans were delivered with a linear accelerator with Gafchromic
EBT-XD film inserted at each site. For each plan, the TPS-calculated and film-measured anteriorposterior (AP) dose profiles through isocenter were obtained and 2D gamma pass rate (GPR) was
calculated at multiple dose difference/distance-to-agreement criteria.
Results: For each TPS-film AP profile pair, the dose falloff difference and profile shift
were measured posterior to the vertebral body. Each sample' normality was confirmed with a
Shapiro-Wilk test, equality of variances was determined between the TPSCS and TPSMC samples
with Levene's test, then an unpaired t-test was used to detect statistically significant differences
between TPSCS and TPSMC (n = 5, α = 0.05). Across the five treatment sites, the mean dose falloff
difference was -0.0 ± 0.8 mm (+0.7 ± 7.8%) in TPSCS and -0.7 ± 0.5 mm (-7.8 ± 6.0%) in TPSMC.
The mean profile shift was -0.1 ± 0.3 mm in TPSCS and +0.0 ± 0.6 mm in TPSMC. No statistically
significant differences were observed in the profile metrics between each TPS. TPSCS yielded
consistently higher average GPR across the sites, with statistically significant differences found
for all criteria tested except 2%/1mm and 1%/1mm. GPR in the critical region for both TPSs
produced very accurate results for all criteria tested except 3%/1mm, 2%/1mm, and 1%/1mm
occasionally.
Conclusion: Each TPS provided similar end-to-end accuracy in the critical region. The
lower GPR in other areas of the TPSMC plans may be increased by adjusting TPS-specific settings
to limit plan complexity.
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Chapter 1. Introduction
1.1. Background
Many types of cancer, including those originating in the pelvis, colon, lung, breast, and
vertebral bodies commonly metastasize to the extradural region of the spinal cord. This produces
symptoms in the patient such as cord compression, vertebral fracture, and most commonly, pain.
Radiation therapy is effective at relieving pain quickly and noninvasively, but care must be taken
to avoid overdosing the spinal cord. This can cause radiation myelopathy, inducing sensory and
motor deficits or even paralysis. Conventional radiation therapy usually involves delivering a
fraction of the total radiation dose daily over several weeks, allowing healthy tissue to repair itself.
Conversely, stereotactic body radiation therapy (SBRT) involves delivering large doses of
radiation in five, three, or sometimes merely one fraction. SBRT is well suited for spinal metastases
due to its higher dose conformity, higher dose gradient, and higher biological effective dose
compared to conventionally fractionated radiotherapy.1
A patient undergoing any type of radiotherapy must first have their treatment simulated on
a computed tomography (CT) scan in a treatment planning system (TPS). The intrinsic accuracy
of a TPS is influenced by several factors, such as patient anatomy, the dose calculation grid, the
optimization methods, and, most notably, the dose calculation algorithm. In spine SBRT treatment
planning, the need for accuracy is particularly important in the high-dose gradient regions2
between the treated vertebral body and the spinal cord and also for the small fields typically utilized
to create such dose distributions.3 Sometimes sub-millimeter accuracy is needed to achieve
sufficient target coverage while sparing the spinal cord.
One class of dose calculation algorithms extensively utilized in radiation treatment
planning is convolution-superposition (CS) models. In these models, dose in each voxel is
calculated deterministically by convolving total energy released per unit mass (terma) with a
polyenergetic dose spread kernel, which has been retrospectively calculated using Monte Carlo
simulations.4, 5 The terma and kernel represent the energy deposited by the primary photons and
secondary interactions, respectively.6–8 To decrease calculation time for clinical use, some
approximations are employed, such as neglecting interactions when they fall below a threshold
terma or occur past a certain distance along the path. Such approximations may lead to inaccuracies
in dose calculation due to the neglecting of some scatter radiation.6
Alternatives to CS models are Monte Carlo (MC) based algorithms, which record the
histories of primary photon interactions and secondary particles per voxel stochastically.
Interactions occur based on linear attenuation coefficients and cross sections, i.e., first principles. 6,
9–11
The statistical accuracy of the calculation is dependent on the number of histories,11 so, for
many years, calculation times were too long for daily use in the clinic. However, advances in
computing speed have increased this algorithm's clinical feasibility. Previous studies have found
that MC-based algorithms generally yield a more accurate calculation than CS-based algorithms
near tissue-bone interfaces1, 3 and in low-density regions.3, 12 The region between the vertebral
body and the spinal cord or cauda equina in spine SBRT plans is an especially crucial tissue-bone
interface.
Previous studies have compared CS-based and MC-based TPSs specifically for spinal
SBRT treatments.3, 13–15 These studies found that both dose calculation methods are currently
capable of producing clinically acceptable plans. However, end-to-end dosimetric verification with
measurements in an anthropomorphic phantom is needed to test the overall accuracy of the
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calculated dose distributions in realistic anatomy. For this study's purposes, end-to-end means
evaluating the accuracy of the dose distributions after incorporating all treatment steps and
accumulating all sources of error, from simulation to delivery.16–18 Such a process for comparing
CS-based and MC-based TPSs with radiochromic film measurements at the spine is lacking within
the currently published literature.
1.2. Hypothesis and Specific Aims
The goal of this study was to investigate and compare the end-to-end dosimetric accuracy
of a CS-based TPS (TPSCS) and an MC-based TPS (TPSMC) for spine SBRT treatments. It was
hypothesized that, for single-fraction spine SBRT treatments, TPSMC would calculate the dose
gradient between the vertebral body and the spinal cord more accurately than TPSCS when
compared to film measurements in an anthropomorphic phantom. This hypothesis was tested
through the following specific aims:
Aim 1: Generate single-fraction spine SBRT treatment plans in TPSCS and TPSMC on an
anthropomorphic phantom.
Aim 2: Deliver the SBRT plans to the phantom and measure the resulting dose distribution using
radiochromic film.
Aim 3: Analyze the film-measured dose distributions around each treatment target and compare
with the TPS-calculated dose planes.

2

Chapter 2. Methods and Materials
2.1. Phantom
The Alderson RANDO anthropomorphic phantom used in this work (Figure 2.1) is made
of soft tissue equivalent material based on the ICRP Standard Man and a natural human skeleton
with soft tissue equivalent material injected into any hollow areas of the bone. The phantom also
contains lung equivalent material, composed of a less dense soft tissue equivalent foam.19 The
phantom is divided transversely into 36 sections, numbered 0 to 35 in the superior-inferior (SI)
direction. Each section is 2.5 cm thick, except for section 35, which mounts to the inferior wooden
frame. A plastic ring mounts section 0 to the superior wooden frame. Adjacent sections are held
together by pairs of internal plastic rods at a 4-inch (10.16 cm) center-to-center distance from each
other in sections 0 to 11. Pairs of plastic rods at a 10.1-inch (25.65 cm) center-to-center distance
connect adjacent sections 11 to 35. The latter pairs of rods can be mounted into either wooden
frame so that only a portion of the phantom sections may be joined if desired (Figure 2.2). The
phantom also contains many removable cylindrical plugs (5 mm diameter) that fill holes designed
for radiation measurement devices. For this study, however, they served as fiducials for film
registration.

Figure 2.1. Alderson RANDO anthropomorphic phantom fully assembled in its frame.
Five vertebral sites, shown in Figure 2.3, were selected for treatment: C4, T1, T12, L2, and
L4, where C stands for cervical vertebra, T for thoracic, and L for lumbar. These sites were chosen
to sample different shaped dose distributions and varying nearby organs at risk (OARs). The
construction of the phantom also warranted that these vertebrae be chosen since each spanned two
sections, split approximately in the middle (Table 2.1), allowing for film dose plane measurements
at these sites.

3

Figure 2.2. Superior phantom frame with internal rod mounting holes and a circular slot for
mounting the head ring (Left). Inferior phantom frame with knobs for mounting to the phantom's
holes (Right).

Figure 2.3. Sagittal view of the phantom CT. The five treatment sites, spinal cord portions, and
cauda equina are contoured in red, cyan, and green, respectively. In the coordinate axes, 'A' is the
anterior direction, 'P' is posterior, 'S' is superior, and 'I' is inferior.
2.2. Treatment Planning
The entire phantom was assembled, and sections 3 to 33 were scanned in a computed
tomography (CT) scanner (Lightspeed RT, General Electric Healthcare, Chicago, Illinois) with a
120 kVp x-ray tube energy, 298 mA tube current, 1.25 mm slice thickness, and a 50 cm field of
view. The selected tube energy was typical of that used to scan patients at our institution, and the
tube current was selected to produce a very high signal to noise ratio. The slice thickness and field
of view combination produced a CT voxel size of 0.97×0.97×1.25 mm3.
Table 2.1. Phantom sections included at each treatment site.
Treatment
Site
C4
T1
T12
L2
L4

Sections Spanning
the Treatment Site
7-8
10 - 11
21 - 22
24 - 25
27 - 28
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At the time of the study, Pinnacle3 v9.10 (Phillips Medical Systems, Fitchburg, Wisconsin)
was the current clinically commissioned system for external beam treatment planning at our
institution and will hereupon be referred to as 'TPSCS.' The phantom's CT images were imported
into TPSCS. For each treatment site, the entire vertebral body and pedicles were contoured as the
clinical target volume (CTV) following international consensus guidelines.20 No gross tumor
volume (GTV) was contoured. Currently, there exists no consensus for planning target volume
(PTV) contouring for spine SBRT, so long as the PTV expands at most 3 mm from the CTV. For
this project, a board-certified radiation oncologist recommended that the PTV be defined as a 2
mm isotropic expansion of the CTV except where the contour would intersect with the cauda
equina or the vertebral foramen area around the spinal cord. Figure 2.4 displays the CTV and PTV
contoured on the T12 site.
The phantom contained no mock spinal cord inside the vertebral bodies, so an approximate
spinal cord was contoured. RTOG 0631 provides SI limits for contouring the spinal cord at each
vertebral site. First, the vertebral foramen was manually contoured from 5 mm above the most
superior slice containing the CTV to 5 mm below the most inferior slice containing the CTV.21
This contour was then contracted 2.5 mm inward transversely (see Figure 2.4) and assigned as the
spinal cord. The cauda equina was manually contoured, beginning 6.25 mm inferior from the most
superior slice of the L2 CTV, and ending 3.75 mm superior to the fourth sacral bone tip. The cauda
equina size varied throughout contour, with a maximum diameter of about 1.8 cm. Points of
interest were defined at the approximate centers of four nearby diode plugs in the transverse plane
where isocenter was at each TPSCS site (Figure 2.4). These markers served as the registration points
for each site.
In addition to the spinal cord and cauda equina, the following mock OARs were contoured
inside the phantom per the RTOG 0631 guidelines: esophagus, trachea and larynx, skin, stomach,
duodenum, renal hilum/vascular trunk, right and left lungs, and right and left renal cortices. The
brachial plexus was also partially contoured adjacent to the C4 and T1 vertebrae, and the sacral
plexus was partially contoured adjacent to the L4 vertebra. The remaining OARs were not
contoured because either their dose constraints were above the prescription dose, or their locations
were far enough from the treatment sites that it was safe to assume they would not exceed their
doses limits.21 An external contour around the entire phantom was also created.
The prescription dose (Rx), target coverage, and hotspot limits also followed RTOG 0631.
Rx was a single fraction of 1600 cGy to at least 90% of the PTV volume. Hot spots greater than
or equal to 1680 cGy (105% of Rx) were limited to a volume of 2 cc or less outside of the CTV
and within 1 cm from the outer edge of the CTV. Hot spots greater than or equal to 1760 cGy
(110% of Rx) were kept within the CTV. The dose limits for the cord were no more than 14 Gy to
0.035 cc and no more than 10 Gy to 0.35 cc or 10% of the volume. The dose limits for the cauda
equina were no more than 16 Gy to 0.035 cc and no more than 14 Gy to 5 cc.21 The dose limits for
the other OARs contoured are listed in Table 2.2.
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Figure 2.4. Transverse CT view of the T12 vertebral site in TPSCS. The CTV is contoured in red,
the PTV in orange, the vertebral foramen in blue, and the spinal cord is shaded in cyan. The
yellow point in the vertebral body is the beam isocenter of the plan, and the multicolored points
around the site are the TPS registration points. In the coordinate axes, 'A' is the anterior direction,
'P' is posterior, 'R' is patient right, and 'L' is patient left.
Table 2.2. OAR dose-volume constraints for the phantom spine SBRT plans, all of which are
designated as serial tissues, except for the lung and renal cortex, which are parallel tissues.
Tissue
Spinal Cord
Cauda Equina
Sacral Plexus
Esophagus
Ipsilateral Brachial Plexus
Trachea & Larynx
Skin
Stomach
Duodenum
Renal Hilum / Vascular Trunk
Lung (Right & Left)
Renal Cortex (Right & Left)

Volume
< 0.035 cc
< 0.35 cc (or 10%)
< 0.035 cc
< 5 cc
< 0.035 cc
< 5 cc
< 0.035 cc
< 5 cc
< 0.035 cc
< 3 cc
< 0.035 cc
< 4 cc
< 0.035 cc
< 10 cc
< 0.035 cc
< 10 cc
< 0.035 cc
< 5 cc
< 2/3 total volume
1000 cc
200 cc

Max Dose to Volume
1400 cGy
1000 cGy
1600 cGy
1400 cGy
1800 cGy
1440 cGy
1600 cGy
1190 cGy
1750 cGy
1400 cGy
2020 cGy
1050 cGy
2600 cGy
2300 cGy
1600 cGy
1120 cGy
1600 cGy
1120 cGy
1060 cGy
740 cGy
840 cGy

Source: Ryu S, et al., RTOG 0631, 201421
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Endpoint
myelitis
neuritis
neuropathy
stenosis / fistula
neuropathy
stenosis / fistula
ulceration
ulceration / fistula
ulceration
malignant hypertension
pneumonitis
basic renal function

The beam model in TPSCS was clinically commissioned according to manufacturer
guidelines. For each treatment plan designed in TPSCS, two separate VMAT beams were defined,
each with an energy of 6 MV FFF (flattening filter free). One arc moved counter-clockwise from
175° (patient right) to 185° (patient left) with a collimator angle of 45°. The other arc moved
clockwise from the same angles in the opposite direction with a collimator angle of 320°.22 The
beam isocenter of each treatment site was placed in the approximate transverse center of the
vertebral body in the CT slice between the two phantom sections that the vertebra was split at. The
dose calculation grid for each treatment site was defined to cover the range of sections listed in
Table 2.3 below, covering nearby OARs. All dose grids had a 2 mm resolution and included the
frame rods of the phantom. The CT scanner's couch was subtracted, overriding the physical density
to match that of air in TPSCS.
Table 2.3. Phantom sections included in each TPSCS dose grid.
Treatment
Site
C4
T1
T12
L2
L4

Sections Included in
TPSCS Dose Grid
3 - 18
3 - 19
17 - 33
20 - 33
20 - 33

1-cm width rings structures were contoured in TPSCS around the CTV and PTV to aid the
inverse optimization (see Appendix A for more details). The final gantry spacing of each plan was
set to 2° per segment, resulting in 352 control points (176 per arc) per plan. The multileaf
collimator (MLC) movement was constrained to 4.6 mm per degree, the minimum dynamic leaf
gap was set to 1 cm, and the opening density matrix was 0.5×0.5 cm2. The convolution dose
iteration was 10 and the stopping tolerance was 1×10-5. The final dose of the plans was calculated
using TPSCS's Adaptive Convolve algorithm, which is a faster variant of its full collapsed-cone
convolution-superposition algorithm that reduces the dose grid in low-dose gradient regions.23 The
density/fluence grid was matched to the dose grid.
Monaco v5.51 (Elekta, Stockholm, Sweden) with its X-ray Voxel Monte Carlo (XVMC)
dose calculation algorithm was chosen as the MC-based TPS used in this study and will be further
referred to as 'TPSMC.' After the five treatment plans were completed in TPSCS, the CT images,
contoured structures, and isocenters were imported into TPSMC (Figure 2.5), whose 6 MV FFF
beam model was commissioned following the manufacturer guidelines. TPSMC automatically filled
any hollow areas of ring-shaped contours imported from TPSCS. This filling of rings took place
around the superior and inferior edges of the C4 and T1 vertebrae and throughout the center of the
T12, L2, and L4 vertebral bodies. This did not affect the main inverse optimization process since
TPSMC's shrink margin feature was used to assist the inverse optimization, but the contours had to
be manually corrected since filling the ring structures changed the dose-volume distribution of
them. See Appendix A for more details.
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Figure 2.5. 3D reconstruction of the phantom CT in TPSMC, showing the vertebral targets and
OARs contoured.
One dual-arc 6 MV FFF beams was defined for each plan in TPSMC. When defining a single
dual-arc beam in TPSMC, the beam is optimized around one half of the target during the first arc,
and the other half during the second arc.24 TPSMC is also capable of changing the degree of
modulation after a user defined arc increment (20° in this case). For the Agility MLC models
(Elekta, Stockholm, Sweden) used in our institution's linear accelerator (linac), TPSMC can utilize
the y-axis jaws of the linac to block the width the MLC leaves in 1 mm increments. These
advantages negated the need to rotate the collimator between VMAT arcs, which remained at 0°
for all beams in TPSMC. A couch structure may be imported into TPSMC, but for this work, the CT
couch was covered with a large structure with its electron density overridden to match that of air.
This was analogous to the couch subtraction method in TPSCS.
In TPSMC, the 2 mm dose calculation grid contained the entire external contour around the
phantom and the four frame rods. The MC dose calculation algorithm's statistical uncertainty was
set to 2% per control point. The first stage of the treatment plan calculation was fluence
modulation, which used a preliminary pencil beam calculation of dose. The second stage was
segmentation, which contained the actual MC dose calculation. The maximum number of control
points allowed was set to 350, but TPSMC automatically varies the control point spacing depending
on the gantry angle and plan optimization objectives.24 Each plan in TPSMC ultimately ended up
with a different number of control points. The minimum segment width was set to 0.5 cm, the
beamlet width was set to 3 mm, and the fluence smoothing was set to medium.25 Smooth segment
optimization (SSO) and high precision leaf positions were enabled, and the speed-to-plan quality
was set to 5. Minimum CT number was -200 and target margin was set to 2 mm (Tight).
After all the spine treatment plans were calculated, they were reviewed for clinical efficacy
by a board-certified radiation oncologist.
2.3. TPSMC Dose Model Validation
To verify the accuracy of the TPSCS and TPSMC dose models, four IMRT plans from AAPM
Task Group Report 119 (TG-119), 'Multitarget,' 'Prostate,' 'Head/Neck,' and 'Cshape (easy
version)' were created in each TPS on solid 30-cm×30-cm stacked solid water slabs (The Original
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Plastic Water, CIRS, Norfolk, Virginia).26 The solid water was CT scanned at the same parameters
as the spine plans, except the tube current was set to 440 mAs and the slice thickness was 2.5 mm.
The contours for the TG-119 validation plans were obtained from the AAPM website.27 All TG119 validation plans were calculated with the same TPS parameters as the spine plans. All plans
in each TPS were single-arc except for the Head/Neck, which was dual-arc.
With the Versa HD linac (SN 153187, Elekta, Stockholm, Sweden), the dose at various
points in the solid water were measured and compared with the calculated dose in the
corresponding TPS with a 0.3 cc ion chamber (Model 31011, SN 0058, PTW, Freiburg, Germany)
cross-calibrated with a 0.6 cc Farmer chamber (Model 30013, SN 03435, PTW, Freiburg,
Germany). The same electrometer (Model 206, SN 11207335, CNMC Company, Inc., Nashville,
Tennessee) was used for all measurements. The source-to-surface distance (SSD) remained 92.5
cm throughout all plans, but the dose at different depths were obtained by rearranging the water
slabs, changing the anterior-posterior (AP) position of the milled slab holding the ion chamber.
The average measured point dose was based on three reading of the ion chamber, corrected
for temperature inside the slab's chamber cavity and for atmospheric pressure. The difference from
the planned point dose was calculated, normalized with respect to the prescribed dose per fraction
for each plan. Confidence limits (CL) were calculated for the mean dose differences in the high
and low dose regions with the following equation:26
CLdiff = |Dose Difference| + 1.96σ
Assuming a normal distribution, this value implies that 95% of measurements in either the
high or low dose region should deviate from the planned dose by ± CLdiff most.
Gamma pass rates (GPR) of the TG-119 validation plans measured on a 2D diode array
(MapCHECK2, Sun Nuclear Corporation, Melbourne, Florida) were compared with those
delivered from the TPSCS plans. Before delivering the plans to the diode array, it was dose
calibrated based on the planned dose calculated in TPSCS at the center of the array, 100 cm sourceto-axis distance (SAD), 10×10 cm2 field size. Gamma analyses were performed in the software
SNC Patient v7.0 (Sun Nuclear Corporation, Melbourne, Florida) at the following dose difference
/ distance to agreement (ΔD/DTA) criteria: 5%/1mm, 3%/3mm, 3%/2mm, 3%/1mm, 2%/2mm,
2%/1mm, and 1%/1mm. ΔD was set to absolute dose (measured - planned), Van Dyk was turned
on, normalized to the maximum planned dose, and measurement uncertainty was applied. A 10%
maximum planned dose threshold was applied to each the gamma analysis. CL was also calculated
for the mean GPR at each gamma criterion with the following equation:26
CLGPR = |100% − Mean GPR| + 1.96σ
Assuming a normal distribution, this value implies that 95% of gamma analyses should
yield GPRs greater than or equal to (100% - CLGPR).
TG-119's preliminary plans, 'AP:PA' and 'Bands' were also made in TPSMC alone, delivered
to a 0.007 cc microchamber (Model A16, REF 92726, SN XAA030841, Standard Imaging,
Middleton, Wisconsin) in the water slabs and to the diode array. In the 'Bands' plan, the dose
difference was, at most, only -1%, with an average difference -0.3% off across all the dose "bands."
At 3%/3mm criteria, GPR was 100% for both P1 and P2, and at 2%/2mm criteria, 99.2% and
99.1% for P1 and P2, respectively (data not shown). Because of the close agreement, these
measurements were not repeated for TPSCS, as it was previously commissioned for clinical use.
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2.4. Film Dosimetry
After the five spine SBRT treatments plans in TPSCS and the five in TPSMC were completed
and approved, the plans were sent to our institution's record and verify system (MOSAIQ v2.81,
Elekta, Sunnydale, CA) and delivered on the previously mentioned linac, measuring the dose with
radiochromic film.
Radiochromic film is a near tissue equivalent passive integrating radiation detector. EBT
brand radiochromic film specifically consists of an active layer of pentacosa-10,-12-diynoic acid
lithium salt (Li-PCDA) sandwiched between two polyester substrates. The Li-PCDA microcrystals
polymerize upon exposure to ionizing radiation, which darkens the film, the intensity of which is
dependent on the dose of radiation. Aluminum oxide nanoparticles in the active layer reduce
energy dependence. When not in use, the film must be stored in darkness to prevent unwanted
polymerization.28 Properly calibrated, radiochromic film provides high-resolution twodimensional dose measurements.
Gafchromic EBT-XD film (Lot 11062002, REF 859138, Ashland LLC, Bridgewater, New
Jersey) was selected for this study for its high saturation dose (40 Gy) and reduced appearance of
lateral response artifacts.28–30 The calibration for this film batch was performed with 15 5×5 cm2
square cuts from a single sheet of radiochromic film using the same linac described previously.
Each film patch was irradiated separately at the following nominal dose values: 0, 24, 36, 60, 80,
120, 180, 280, 400, 620, 920, 1380, 1600, 2000, 2500 cGy (Figure 2.6).
The linac's 6 MV beam was calibrated to a nominal output of 0.8 cGy per monitor unit
(MU) for a 0.6 cc Farmer chamber at 100 cm SAD, a 10 cm depth (the TG-51 measurement depth
of the linac28), 11 cm of backscatter material, and a 10×10 cm2 field size. Before irradiation of the
calibration films, the linac output for that day was measured by delivering 100 MU of the 6 MV
beam to the previously described Farmer chamber at the above conditions. Three output
measurements were recorded with an electrometer (Model 206, SN 11401357, CNMC Company,
Inc., Nashville, Tennessee), then averaged for that treatment day. All chamber measurements were
corrected for temperature inside the slab's chamber cavity and for atmospheric pressure. The
calculated measured dose per MU was used to determine the actual dose delivered to each
calibration patch.
After the linac output measurement, each calibration film was irradiated perpendicular to
the beam axis between solid water slabs at the same conditions described above, but with 10 cm
of backscatter material. The flattening filter was included in calibration for a more uniform dose
distribution.
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Figure 2.6. The 15 calibration films immediately after irradiation.
Approximately 48 hours after irradiation of the last calibration film, the films were scanned
together in a color flatbed scanner (Epson Expression 10000XL, Epson America, Los Alamitos,
California). Forty-eight hours was selected as the minimum post-exposure interval since
radiochromic film response increases rapidly within the first 24 hours after irradiation but plateaus
afterward.28, 31 The scan was performed with all films in landscape orientation at 150 DPI (0.169
mm pixel size), 48-bit color, 16.5 inches×12.2 inches, and in transmission mode. All image
enhancements were disabled.
Before scanning the experimental films, however, five preview warmup scans were
performed to reduce film response differences due to temperature changes. A 2 mm glass plate
was also placed over the films in the scanner bed (including the scanner's calibration area) to ensure
film flatness and avoid the Callier effect.28 This glass plate was cleaned with isopropyl alcohol
then dusted with a microfiber cloth before each scanning session. The scanner bed was dusted as
well.
The scanned calibration films were saved as .tiff files and imported into a commercial film
analysis software package (RIT113 Classic v6.5, Radiological Imaging Technology, Inc.,
Colorado Spring, Colorado). Using the software, the pixel values (PVs) of the red, green, and blue
(RGB) channels were averaged together and a 5×5-pixel median filter was applied by default to
reduce noise. A 3×3 cm2 region of interest (ROI) was placed over each calibration film in the scan
to get a mean PV and standard deviation for each dose. The delivered dose value for each irradiated
film patch was entered, forming the calibration curve fitted to a piecewise polynomial.32 A profile
was also placed along each calibration patch to confirm that the variation was below 3%.28
On the day of each spine plan delivery, the linac output was measured at the same
conditions as before (0.6 cc Farmer chamber, 100 cm SAD, 10 cm depth, 11 cm backscatter
material, 10×10 cm2 field size, temperature, and pressure corrections), this time with a 6 MV FFF
beam. The same electrometer was used for all treatment days except for the day of the L4 site
treatment when it unavailable. A substitute electrometer (Model 206, SN 10812253, CNMC
Company, Inc., Nashville, Tennessee) was used instead. These output measurements were
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performed to scale each film's dose values before the analysis and reduce dosimetric effects of
daily output variations. Three output measurements were recorded, then averaged for each
treatment day.
For each treatment site, an 8-inch×10-inch film sheet was cut in half parallel to the short
edge. This half was then cut to the outline of the phantom section of the current treatment site and,
if necessary, cut to avoid contact with the pair of internal plastic rods that connect each section.
Each film was labeled according to its treatment site (C4, T1, etc.), TPS (TPSCS or TPSMC), and
trial (A, B, or C). The left, right, anterior, and posterior directions were labeled as well. The labeled
film was taped between the phantom sections of the appropriate treatment site, shown in Table 2.4,
then the four registration points were marked with a fine-tipped permanent marker through the
film at the center of the diode plugs.
Separating the phantom sections after each treatment sometimes caused the edges of the
film to delaminate. Since the registration points of the T12, L2, and L4 sites were placed near the
edge of the film, four additional backup registration points were also marked closer to the middle
of the film for these treatment sites (Figure 2.7). Ultimately, though, none of these backup
registration points were needed during analysis.
Table 2.4. Phantom sections where the film was inserted, and the surrounding sections assembled
for each treatment site.
Treatment
Site
C4
T1
T12
L2
L4

Sections Adjacent
to Film
7-8
10 - 11
21 - 22
24 - 25
27 - 28

TPSCS 10 cGy
Isodose Limits
5 - 10
7 - 14
18 - 26
20 - 29
23 - 32

Sections Assembled
During Treatment
0 - 13
0 - 13
15 - 28
18 - 31
21 - 34

To allow for easier phantom handling, only a portion of the whole phantom was assembled
per treatment site (Figure 2.8). The sections of the phantom assembled for each site are also listed
in Table 2.4. For treatment sites T12, L2, and L4, 14 phantom sections were assembled, with the
film inserted at the transverse isocenter plane of the beam in the middle (7 sections were superior
and 7 sections were inferior to the film). This range of phantom sections fully contained 10 cGy
isodose volume calculated by TPSCS. The location of the C4 and T1 sites, however, warranted the
need for the plastic ring, and thus section 0 of the phantom, to mount the phantom to the superior
frame (Figure 2.2). This meant that the films for the C4 and T1 treatments did not have the same
number of sections superior and inferior to them. Sections 0 to 13 still contained the full 10 cGy
isodose volume for C4 and almost the full 10 cGy isodose volume for T1, however.
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Figure 2.7. Film inserted at the T12 site prior to delivering a plan from TPSMC. The four points
marked on the outermost diode plugs (solid circles) were the primary registration points,
corresponding with the TPS registration points in Figure 2.4. The inner four marks (dotted
circles) were backup registration points in case film delamination occurred. Note that the
registration point layout is mirrored compared to that in Figure 2.4 since the left and right
directions are flipped from the CT transverse view.

Figure 2.8. The phantom assembled for the C4 and T1 treatment sites. The orange dotted line
marks the plane where the C4 film was inserted, and the yellow dotted line marks where the T1
film would be inserted.
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After the phantom was assembled with the film securely taped inside, the phantom was
laid supine on the treatment couch and the treatment site was aligned by eye to the treatment room
lasers. The HexaPOD frame, which enables the HexaPOD couch equipped on the linac to adjust
in six degrees of freedom, was mounted on the couch as close to isocenter as possible without
covering the path of the primary beam, following the institution's standard operating procedure. A
kV cone beam CT (CBCT) image was then performed on the phantom with a small field of view
and F1 and S20 filters. After registering the CBCT image to the original planning CT using the
Grey Value (T + R) method in the XVI software (Elekta, Stockholm, Sweden), the HexaPOD
couch was automatically moved to the corrected position, shifting in the three cardinal directions
as well as the pitch, roll, and yaw angular directions. Once the phantom was properly aligned, the
treatment plan was delivered (trial A). The film was promptly removed from the phantom, and the
time of irradiation was noted on it. The same treatment plan was then delivered to two more films
(trials B and C) for that treatment site, following the same setup, imaging, and alignment process.
2.5. Film Analysis
All 30 measurement films (5 plans for each TPS, 3 trials delivered per plan) were digitized
with the flatbed scanner. Like the calibration films, 48 hours was the minimum post-exposure time,
but none of the measurement films exceeded a 51 hour wait time. The scanner parameters and
cleaning process for the glass plate were identical to that of the calibration films. Each
measurement film was scanned individually in its landscape orientation, approximately along the
lateral central axis of the scanner bed at 150 DPI (0.169 mm pixel size), 48-bit color, 16.5
inches×12.2 inches, transmission mode, with no image enhancements. See Figure 2.9 for an
example.
The films scans were saved as .tiff files. Each film scan was opened in the commercial film
analysis software as the 'Reference' image with a 5×5-pixel median filter applied. The calibration
curve was applied to the image, then the image was scaled by the following factor to reduce the
effect of daily linac output variations:
0.8 cGy/ MU
treatment day′s output (cGy/MU)
Each film scan was digitally rotated and mirrored so that the film coordinate system
matched that of the TPS dose plane, then the film scan was assigned as the 'Target' image. The
corresponding TPS dose plane (exported with 1 mm resolution that was interpolated from the 2
mm dose grid resolution) was then opened as the 'Reference' image.
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Figure 2.9. TPSMC T12 film scan, trial A. The circled registration points correspond to those
marked in Figure 2.7.
Prior to the analysis, a registration template for each vertebral site was defined in the film
analysis software. Each registration template was defined using the Right/Left (+x/-x) and
Superior/Inferior (+y/-y) coordinates of the registration points in TPSCS. TPSCS displays
coordinates relative to the CT image's DICOM origin point, but since each dose plane was exported
into the film analysis software with its isocenter at the center of the image, the original coordinates
of each registration point had to be shifted relative the distance from the isocenter to the DICOM
origin. The appropriate registration template was applied to 'Reference' TPS image, then the
corresponding digital registration points were placed manually at the marks on the 'Target' film
image. This registration caused the film image's resolution, 0.169 mm, to downscale to that of the
TPS image, 1 mm. The software also outputted standard deviations of each film's registration based
on a method described by Fitzpatrick et al.33
After registration of the TPS and film images, a limited ROI was defined in TPS image.
Using the known coordinates from TPSCS of each site's isocenter, the coordinates of various points
of interest, such as the edges of the PTV and cord/cauda, were used to locate the same points in
the analysis image. This allowed an ROI to be defined in the software, extending vertically 1 cm
above each site's anterior PTV edge to 1 cm below the posterior cord/cauda edge. This vertical
length ensured an appropriate margin existed for the AP profile analyses. For sites C4 and T1, the
ROI extended horizontally 3 cm from the center of the spinal cord/cauda equina in both the left
and right directions. For the T12, L2, and L4 sites, it extended 4 cm. These horizontal widths
produced sufficient coverage for the gamma analyses. Identical ROI were automatically generated
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on the registered film images. For both TPSs and across the multiple trials for each treatment site,
the ROI location and size were constant. For example, the C4 and T1 sites had different ROI sizes,
but the C4 ROI had the same size and location across all trials for both TPSs, and the T1 ROI had
the same size and location across all trials for both TPSs.
In this ROI, the AP dose profiles through isocenter for both the TPS and film images were
exported and analyzed in a custom MATLAB script (R2021b, MathWorks, Natick,
Massachusetts). The two main metrics used to compare the TPS-calculated and film-measured AP
dose profiles were the dose falloff difference and profile shift.
For each TPS and film profile, two positions, Dhigh and Dlow, were first determined (see
Figure 2.10 for an example). Dhigh is the last position of the 1600 cGy isodose value before the
negative slope of the profile begins. Dlow is the first position on the profile that reaches a threshold
dose gradient of -500 cGy/cm after the negative slope begins. The profiles for the L4 TPSMC plans,
however, did not reliably reach this dose gradient, so a threshold value of -200 cGy/cm was used
instead.

Figure 2.10. TPSCS-calculated and film-measured dose profiles for the T1 site, Trial B. The
shaded region represents the area between the posterior PTV edge and the anterior cord edge.
Dhigh is the last profile position of the 1600 cGy isodose value, and Dlow is the first profile
position that reaches -500 cGy/cm. The dose falloff difference is the positive distance (mm)
measured between Dhigh and Dlow on the TPS profile subtracted from the same distance measured
on the film profile. The profile shift, ΔDmid, is the TPS profile's Dhigh and Dlow midpoint position
(mm) subtracted from the position that matches the same dose value on the film profile.
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The dose falloff difference was defined as the positive distance (mm) measured between
Dhigh and Dlow on the TPS profile subtracted from the same distance measured on the film profile
(Figure 2.10). In addition, the dose falloff percent difference was calculated by normalizing the
dose falloff difference by the current TPS profile's dose falloff as in the below equation:
(Dose falloffFilm − Dose falloffTPS )
× 100%
Dose falloffTPS
A positive dose falloff difference indicates the film profile has a more gradual dose slope
relative to the TPS profile. A negative dose falloff difference indicates the film had a sharper slope.
A difference of zero would be ideal.
The profile shift, ΔDmid, was defined as the TPS profile's Dhigh and Dlow midpoint position
(mm) subtracted from the position that matches the same dose value on the film profile (Figure
2.10). A positive profile shift indicates the film profile was shifted posterior to the TPS profile,
and a negative profile shift indicates an anterior shift. A shift of zero would be ideal.
It was assumed that the average dose falloff difference and average profile shift across each
site's three trials were sampled from normally distributed populations of equal variance. Normality
was confirmed with a Shapiro-Wilks test run on each TPS sample using the shapiro.test34 function
in a custom R v4.0.1 (R Foundation, Vienna, Austria) script. A Shapiro-Wilk p-value greater than
an α value of 0.05 would indicate that each sample comes from a normally distributed population.
Equal variances were confirmed between the TPSCS and TPSMC samples with the vartestn function
in MATLAB, with the test type set to 'LeveneAbsolute.' A Levene p-value greater than the same
α value would indicate that the two TPS samples come from populations of equal variance. A twotailed, unpaired, equal variance t-test was then performed on each TPS sample of metrics using
MATLAB's ttest2 function.35 A T-test p-value less than α would indicate a statistically significant
difference exists between the two samples.
The film analysis software performed 2D gamma analysis36 on the three trials for each
treatment site at the same ΔD/DTA criteria as the TG-119 validation plans: 5%/1mm, 3%/3mm,
3%/2mm, 3%/1mm, 2%/2mm, 2%/1mm, and 1%/1mm. All the ΔD refer to the percentage of
global maximum planned dose. A 10% maximum planned dose threshold was applied as well, but
such low dose values ultimately did not appear in the ROI. The three GPRs for each site were then
averaged.
With the previously described code, using an α of 0.05 throughout, the Shapiro-Wilk test
was performed on each ΔD/DTA criteria sample of GPR to confirm the samples came from
normally distributed populations. Levene's test was performed between the TPSCS and TPSMC
average GPRs for each criterion to determine whether there were equal variances between the two
TPS samples. If variances were equal, an unpaired equal variance t-test was then performed on the
samples. If unequal, an unpaired unequal variance t-test was used.
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Chapter 3. Results
3.1. Treatment Planning Results
Table 3.1 displays the TPSCS and TPSMC spine planning results for each treatment target.
The TPSMC plans always had a lower overall maximum dose. While all plans in TPS CS had their
global maximum dose points inside the CTV, per the advice of the approving radiation oncologist,
all plans except for L4 in TPSMC had the maximum dose point fall within 2 mm outside of the
CTV (within the PTV). For most spine plans, TPSMC generated around twice as many MUs than
TPSCS, which resulted in much longer beam-on times during each treatment. The number of control
points per plan were similar between TPSCS and TPSMC. The one exception was the T12 plans,
which had 99 fewer control points in TPSMC than TPSCS. Though the PTV coverage of the TPSMC
sites were initially higher than shown in Table 3.1, the coverage had to be lowered to a set value
in order to limit dose hotspots greater than 1680 cGy (105% Rx), which were larger in TPSMC than
in TPSCS for all sites except C4 and L4. Despite this, the TPSMC plans consistently yielded higher
PTV coverage than the TPSCS plans, albeit at worse Paddick conformity indices.37
Table 3.2 shows the planning results for the spinal cord and cauda equina. The TPSMC plans
spared the spinal cord more than those in TPSCS after fewer optimizations. The L4 plan in TPSMC
also spared the cauda equina more than the L4 plan in TPSCS.
The calculated transverse dose planes at each treatment site's isocenter are displayed in
Figure 3.1 through Figure 3.5. The isocenter inside the vertebral body as well as the four
registration points for each site are displayed on the TPSCS dose maps. The CTV is contoured in
red, the PTV in orange, the spinal cord in cyan, and the cauda equina in green. As a whole, TPS CS
produced colder dose plans than TPSMC.
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Table 3.1. Planning results of the target volume coverage in TPSCS and TPSMC. All dose values are based on a 0.001 cc volume. The
record and verify system rounded the MUs to the nearest 0.1 MU and defined one additional control point per arc in the TPSMC plans.
Site

C4

T1

T12

L2

L4

TPS

Max Dose
(cGy)

Total
MU

Total
Control Points

105% Isodose Volume
Outside CTV
(cc)

Max Dose Outside
CTV, PTV
(cGy)

CTV, PTV Rx Coverage
(%)

Conformity Index

TPSCS

1770.1

3300.0

352

1.339

1747.2, 1682.0

94.51, 94.32

0.83

TPSMC

1757.0

5073.9

339

0.862

1757.0, 1737.5

96.37, 95.00

0.73

TPSCS

1783.3

4174.0

352

0.570

1747.1, 1647.0

97.61, 91.38

0.93

TPSMC

1740.0

8754.8

345

1.576

1740.0, 1738.4

96.56, 93.01

0.75

TPSCS

1779.8

4194.0

352

1.122

1739.6, 1675.5

95.77, 93.25

0.91

TPSMC

1738.0

8547.7

253

1.813

1738.0, 1727.0

95.02, 94.30

0.77

TPSCS

1782.5

3800.0

352

0.556

1748.1, 1647.3

99.62, 92.18

0.95

TPSMC

1740.0

7423.6

374

1.269

1740.0, 1704.3

99.72, 97.75

0.83

TPSCS

1751.2

3469.0

352

1.056

1713.2, 1661.8

99.89, 93.15

0.96

TPSMC

1734.0

7581.8

387

0.571

1721.5, 1699.5

98.04, 95.24

0.79
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Table 3.2. Planning results for the spinal cord and cauda equina in TPSCS and TPSMC. All dose values are based on a 0.001 cc volume.
Site

C4

T1

T12

L2

L4

TPS

Spinal Cord Volume Receiving 10 Gy
(%, cc)

Max Cord Dose
(cGy)

Cauda Equina Volume Receiving 14 Gy
(cc)

Max Cauda Dose
(cGy)

TPSCS

7.78, 0.172

1364.2

-

-

TPSMC

3.09, 0.065

1157.4

-

-

TPSCS

6.19, 0.156

1284.6

-

-

TPSMC

4.81, 0.121

1259.0

-

-

TPSCS

7.86, 0.219

1244.6

-

-

TPSMC

4.30, 0.121

1192.5

-

-

TPSCS

8.18, 0.060

1218.0

0.076

1506.5

TPSMC

5.37, 0.039

1186.0

0.485

1515.5

TPSCS

-

-

1.013

1571.5

TPSMC

-

-

0.645

1552.0
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Figure 3.1. Calculated transverse dose distribution at the C4 site in TPSCS (Left) and TPSMC
(Right).

Figure 3.2. Calculated transverse dose distribution at the T1 site in TPS CS (Left) and TPSMC
(Right).
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Figure 3.3. Calculated transverse dose distribution at the T12 site in TPS CS (Left) and TPSMC
(Right).

Figure 3.4. Calculated transverse dose distribution at the L2 site in TPS CS (Left) and TPSMC
(Right).
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Figure 3.5. Calculated transverse dose distribution at the L4 site in TPS CS (Left) and TPSMC
(Right).
3.2. Validation Plan Results
Table 3.3 displays the total MU and total number of control points generated in the TG119 validation plans. As in spine plans, TPSMC generated more MUs than TPSCS, except at the
Cshape site. The number of controls points between each TPS were similar except for at the
Head/Neck site, with TPSMC generating 76 fewer than TPSCS.
Table 3.3. Total MUs delivered and total number of control points created for each TG-119 site
and TPS. The record and verify system rounded the MUs to the nearest 0.1 MU and defined one
additional control point per arc in the TPSMC plans.
TG-119 Site
Multitarget
Prostate
Head/Neck
Cshape

TPS

Total MU

TPSCS
TPSMC
TPSCS
TPSMC
TPSCS
TPSMC
TPSCS
TPSMC

359.0
850.1
307.0
517.3
1118.0
1336.9
1056.0
1058.7

Total Number of
Control Points
176
194
176
181
352
276
176
177

The point doses of the validation plans delivered to solid water slabs are displayed in Table
3.4 through Table 3.7. All high-dose points were more accurate in TPSMC than in TPSCS. All lowdose points, except for the head/neck isocenter, were more accurate in TPSCS than in TPSMC. The
average low-dose points across the four plans had similar accuracy between both TPSs, though
TPSMC had a lower σ. In both TPSs, the validation plan's high dose and low dose point
measurements, averaged across the four plans, were not as accurate as the institutional averages
from the published task group report, -0.2% and +0.3% dose differences, respectively. The point
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with the highest difference was in the high dose region of the Cshape plan (for 6.7% TPS CS and
4.6% for TPSMC).
The validation plans delivered to the diode array yielded GPRs displayed in Figure 3.6 and
Figure 3.7 as well as Table 3.8 and Table 3.9. The gamma analyses showed that, at 2%/2mm
criteria, the most common area of failure was inside the targets. For the multitarget plan, the GPRs
of TPSCS were comparable to TPSMC for all criteria except 1%/1mm. For the prostate, both
planning systems yielded similar GPR for all criteria except 3%/1mm, 2%/1mm, and 1%/1mm,
where TPSMC GPR was higher. For the head/neck site, TPSCS GPRs were consistently higher than
TPSMC GPRs for all criteria except 5%/1mm. For the Cshape plan, TPS MC always outperformed
TPSCS. Overall, averaging the GPR across all four sites for each gamma criteria yielded very
similar GPRs for all criteria except for 3%/1mm, 2%/1mm, and 1%/1mm, with TPS MC having
higher GPRs for these. In summary, at 1mm DTA (excluding 5%/1mm), TPSMC tended to have
higher GPRs than TPSCS.
The average 3%/3mm GPR across the TG-119 sites for TPSCS and TPSMC was 99.6% and
99.5%, respectively. These both exceeded the published TG-119 institutional average, 97.9%. The
average 2%/2mm GPR across the TG-119 sites for TPSCS and TPSMC was also very high, 97.4%
and 97.5%, respectively.
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Table 3.4. Point dose measurements for the TPSCS validation plans in solid water slabs. The isocenter planned doses are based on
mean dose to a contoured ion chamber volume (0.081 cc). The other planned doses are based on the absolute point dose.
TPSCS
TG-119 Site

Prescribed Dose
(cGy per fraction)

Multitarget

200

Prostate

180

Head/Neck

200

Cshape
(easy)

200

Measurement Point
(Dose Region)
Isocenter (High)
4 cm Superior (Low)
4 cm Inferior (Low)
Isocenter (High)
2.5 cm Posterior (Low)
Isocenter (High)
4.0 cm Posterior (Low)
Isocenter (Low)
2.5 cm Anterior (High)

Planned Dose
(cGy)
209.04
132.01
64.58
194.60
147.98
220.88
123.14
62.52
218.56

Mean Measured Dose ± σ
(cGy)
213.77 ± 0.00
136.17 ± 0.23
62.49 ± 0.09
199.57 ± 0.00
149.46 ± 0.09
231.34 ± 0.35
132.64 ± 0.30
62.59 ± 0.09
232.05 ± 0.30

Dose Difference
(%)
+2.4
+2.1
-1.0
+2.8
+0.8
+5.2
+4.7
+0.0
+6.7

Table 3.5. Mean dose difference ± σ, and CLdiff for the high and low dose points for the TPSCS validation plans.
High Dose Regions
Low Dose Regions

Mean Dose Difference ± σ (%)
+4.3 ± 2.1
+1.3 ± 2.2

CLdiff (%)
8.3
5.7

Table 3.6. Point dose measurements for the TPSMC validation plans in solid water slabs. The isocenter planned doses are based on
mean dose to a contoured ion chamber volume (0.067 cc). The other planned doses are based on the mean dose to the points, which
had a custom-sized volume of 0.007 cc.
TPSMC
TG-119 Site

Prescribed Dose
(cGy per fraction)

Multitarget

200

Prostate

180

Head/Neck

200

Cshape
(easy)

200

Measurement Point
(Dose Region)
Isocenter (High)
4 cm Superior (Low)
4 cm Inferior (Low)
Isocenter (High)
2.5 cm Posterior (Low)
Isocenter (High)
4.0 cm Posterior (Low)
Isocenter (Low)
2.5 cm Anterior (High)

Planned Dose
(cGy)
208.20
130.76
88.89
193.24
127.58
211.66
112.70
48.42
206.18

Mean Measured Dose ± σ
(cGy)
211.80 ± 0.00
137.88 ± 0.46
92.25 ± 0.23
196.90 ± 0.00
130.02 ± 0.17
220.31 ± 0.31
109.33 ± 0.23
50.06 ± 0.17
215.43 ± 0.30

Dose Difference
(%)
+1.8
+3.6
+1.7
+2.0
+1.4
+4.3
-1.7
+0.8
+4.6

Table 3.7. Mean dose difference ± σ, and CLdiff for the high and low dose points for the TPSMC validation plans.
High Dose Regions
Low Dose Regions

Mean Dose Difference ± σ (%)
+3.2 ± 1.5
+1.1 ± 1.9

25

CLdiff (%)
6.1
4.8

(a)

(b)

(c)

(d)

Figure 3.6. GPR for each TPS at multiple ΔD/DTA criteria for each TG-119 treatment site: (a) Multitarget, (b) Prostate,
(c) Head/Neck, and (d) Cshape.

26

Figure 3.7. Mean GPR across all TG-119 treatment sites for each TPS at multiple ΔD/DTA
criteria. The error bars extend plus and minus one sample σ of the mean.
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Table 3.8. GPR at multiple ΔD/DTA criteria for the TPSCS validation plans.
ΔD/DTA Criteria
5%/1mm
3%/3mm
3%/2mm
3%/1mm
2%/2mm
2%/1mm
1%/1mm

Multitarget GPR
(%)
99.1
100.0
99.3
97.0
98.6
93.7
81.2

Prostate GPR
(%)
99.7
100.0
100.0
96.0
100.0
94.0
84.8

Head/Neck GPR
(%)
98.4
99.5
99.3
97.0
97.9
93.1
81.4

Cshape (easy) GPR
(%)
95.8
98.8
97.7
91.2
93.1
83.3
75.0

Mean GPR ± σ across sites
(%)
98.25 ± 1.72
99.58 ± 0.57
99.08 ± 0.97
95.30 ± 2.77
97.40 ± 3.00
91.03 ± 5.16
80.60 ± 4.08

CLGPR
(%)
5.1
1.5
2.8
10.1
8.5
19.1
27.4

Table 3.9. GPR at multiple ΔD/DTA criteria for the TPSMC validation plans.
ΔD/DTA Criteria
5%/1mm
3%/3mm
3%/2mm
3%/1mm
2%/2mm
2%/1mm
1%/1mm

Multitarget GPR
(%)
98.8
99.8
99.3
96.3
97.7
92.8
84.1

Prostate GPR
(%)
99.6
100.0
100.0
98.2
99.6
96.8
88.5

Head/Neck GPR
(%)
98.8
98.2
97.8
94.7
94.1
90.4
79.2
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Cshape (easy) GPR
(%)
98.5
99.8
99.8
96.9
98.7
93.4
88.4

Mean GPR ± σ across sites
(%)
98.93 ± 0.47
99.45 ± 0.84
99.23 ± 0.99
96.53 ± 1.45
97.53 ± 2.41
93.35 ± 2.64
85.05 ± 4.41

CLGPR
(%)
2.0
2.2
2.7
6.3
7.2
11.8
23.6

3.3. Film Calibration Curve
On the day of calibration film irradiation, the linac output was 0.8099 cGy/MU at the
calibration conditions. This value was multiplied by the MU delivered per calibration patch to
obtain the actual calibration dose values listed in Table 3.10.
Figure 3.8 displays the calibration curve for the film batch. Each point represents the mean
of the red, green, and blue channel PVs of the ROI over each calibration patch. A 3.62 cm long
profile was also placed across the approximate center of each calibration patch along the films'
landscape axis. The maximum and minimum PV along the profile were identified, then the percent
difference relative to the profile's mean PV was calculated for each. The larger percent difference
is displayed in Table 3.10, all of which were within 3% uniformity per TG-235 guidelines.28 The
largest variation occurred in 400 and 620 cGy calibration films.
Table 3.10. Nominal calibration dose values, actual dose values adjusted with the linac output
measurement, and largest percent difference from mean PV in each calibration patch.
Nominal Calibration Dose
(cGy)
0
24
36
60
80
120
180
280
400
620
920
1380
1600
2000
2500

Actual Calibration Dose
(cGy)
0.0
24.3
36.4
60.7
81.0
121.5
182.2
283.5
404.9
627.7
931.4
1397.1
1619.8
2024.7
2530.9

Largest Percent Difference
(%)
0.66
0.38
-0.81
-0.75
-0.44
-1.04
-0.80
0.86
-1.38
-1.33
0.80
0.71
0.93
-0.87
-0.82

3.4. Spine Plan Film Results
Both the dose falloff difference and profile shift were obtained from the TPS-film profile
pair for each trial delivered, then the metrics from the three trials were averaged for each treatment
site. Table 3.11 and Table 3.12 display the average dose falloff difference ± standard deviation (σ)
and average profile shifts ± σ for each treatment site, respectively. They also display the mean
value of each metric ± σ across the five treatment sites for each TPS. The p-values for each
statistical test are displayed as well.
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Figure 3.8. Mean RGB calibration curve for the Gafchromic EBT-XD film batch fit to a
piecewise polynomial. The error bars at each point extends plus and minus one sample standard
deviation (σ) of the mean PV in each calibration patch's ROI.
The largest dose falloff differences took place in the L4 TPSCS plan at -1.1 ± 1.0 mm
(-7.8 ± 7.1%) and the L4 TPSMC plan at -1.5 ± 1.0 mm (-16.6 ± 10.7%). The smallest difference
took place in both the C4 and T12 TPSCS plans, at -0.3 ± 0.5 mm (-2.9 ± 5.7%) and -0.3 ± 0.8 mm
(-3.5 ± 11.2%), respectively. In TPSMC, the T1 plan had the smallest difference at -0.1 ± 0.3 mm
(-1.3 ± 3.2%). The average dose falloff differences for all treatment sites for TPS CS and TPSMC
were -0.0 ± 0.8 mm (+0.7 ± 7.8%) and -0.7 ± 0.5 mm (-7.8 ± 6.0%), respectively. On average, any
dose falloff differences between the TPS-calculated and the film-measured AP profiles in the
critical region between the PTV and cord/cauda were smaller than the resolution of the dose planes.
The largest profile shifts took place in the T1 plan for both TPSCS and TPSMC, -0.6 ± 0.2
mm and -0.9 ± 0.0 mm, respectively. The smallest shift in TPSCS took place in both C4, +0.2 ± 0.1
mm, and L2, -0.2 ± 0.2 mm. In TPSMC, the smallest shift was at L2, +0.2 ± 0.1 mm. The average
profile shift across all treatment sites for TPSCS and TPSMC were -0.1 ± 0.3 mm and +0.0 ± 0.6
mm, respectively. Again, any profile shifts between the calculated and measured profiles in the
were smaller than the dose distribution's resolution.
Each TPS sample was confirmed to come from normally distributed populations of with
equal variance to its opposing TPS. No statistically significant differences were detected in the
dose differences, dose falloff differences, or profile shifts between TPSCS and TPSMC. The dose
profiles for all trials are compiled in Appendix B.
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Table 3.11. AP dose falloff differences and percent dose falloff differences between the TPS-calculated and film-measured profiles of
TPSCS, likewise for TPSMC, and the p-values of the statistical tests.
Treatment Planning System

-1.1 ± 1.0

Mean ± σ
across sites
-0.0 ± 0.8

Shapiro-Wilk
p-value
0.606

-1.5 ± 1.0

-0.7 ± 0.5

0.460

+10.7 ± 4.7

-7.8 ± 7.1

+0.7 ± 7.8

0.436

-11.0 ± 1.9

-16.6 ± 10.7

-7.8 ± 6.0

0.615

C4

T1

T12

L2

L4

TPSCS Dose Falloff Difference (mm)

-0.3 ± 0.5

+0.6 ± 0.4

-0.3 ± 0.8

+0.8 ± 0.4

TPSMC Dose Falloff Difference (mm)

-0.4 ± 0.2

-0.1 ± 0.3

-0.5 ± 0.3

-0.8 ± 0.1

TPSCS Dose Falloff Difference (%)

-2.9 ± 5.7

+7.1 ± 4.7

-3.5 ± 11.2

TPSMC Dose Falloff Difference (%)

-5.1 ± 2.8

-1.3 ± 3.2

-5.2 ± 3.6

Levene
p-value

T-Test
p-value

0.325

0.167

0.341

0.088

Table 3.12. AP profile shifts between the TPS-calculated and film-measured profiles of TPSCS, likewise for TPSMC, and the p-values
of the statistical tests.
Treatment Planning System
TPSCS Profile shift (mm)
TPSMC Profile shift (mm)

C4

T1

T12

L2

L4

+0.2 ± 0.1
-0.3 ± 0.1

-0.6 ± 0.2
-0.9 ± 0.0

-0.3 ± 0.1
+0.4 ± 0.2

-0.2 ± 0.2
+0.2 ± 0.1

+0.3 ± 0.5
+0.7 ± 0.3

31

Mean ± σ
across sites
-0.1 ± 0.3
+0.0 ± 0.6

Shapiro-Wilk
p-value
0.680
0.855

Levene
p-value

T-Test
p-value

0.212

0.655

The average GPR across the three trials for each site and TPS as well as the average GPR
across all sites are displayed in Figure 3.9 and tabulated in Table 3.14 and Table 3.15. For all
criteria, except 5%/1mm and 1%/1mm, Levene's test yielded unequal variances between the
sample of TPSCS GPRs and sample of TPSMC GPRs (Table 3.16). An unpaired unequal variance
t-test was performed on all samples of criteria, except for 5%/1mm and 1%/1mm, which received
the equal variance t-test. Averaging across the three trials, TPSCS always obtained a higher mean
GPR than TPSMC at all sites, except for the 1%/1mm gamma analysis of T12. The differences in
GPR between each TPS were statistically significant for all criteria all except 2%/1mm and
1%/1mm.
Appendix C displays figures of the digitized film measurements for all trials, where the red
pixels represent the dose points calculate that a gamma value larger than 1, i.e., failed the test, for
the 2%/2mm criteria. The most common area for points to fail was inside the PTV, specifically the
posterior portion, which usually had a higher measured dose than planned. TPSMC consistently had
more failing points inside the PTV compared to TPSCS. TPSMC also had overestimated dose points
immediately posterior to the spinal cord and cauda equina for all sites except C4. Such failures
occurred minorly in TPSCS at the T1 site. Points near the edge of their ROI tended to fail for both
TPSs. The area between the posterior PTV edge and anterior cord/cauda edge usually failed at
either 3%/1mm, 2%/1mm, or 1%/1mm criteria (Table 3.13).
Table 3.13. Gamma criteria where dose points between the posterior PTV edge and anterior
cord/cauda edge tend to fail. Each listed criterion was determined based on a qualitative
observation of each site's three trials for per TPS.
Vertebral Site
C4
T1
T12
L2
L4

TPS
TPSCS

ΔD/ DTA of Failure
-

TPSMC
TPSCS

-

TPSMC

3%/1mm

TPSCS

3%/1mm

TPSMC

3%/1mm

TPSCS

1%/1mm
3%/1mm

TPSMC
TPSCS
TPSMC
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2%/1mm
1%/1mm

(a)

(b)

(c)

(d)

Figure 3.9. Trial average GPR at each treatment site for each TPS at multiple ΔD/DTA criteria: (a) C4, (b) T1, (c) T12, (d) L2, (e) L4,
and (f) mean across all sites. The error bars extend plus and minus one sample σ of the mean.
(figure cont'd.)
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(e)

(f)
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Table 3.14. GPR ± σ at multiple ΔD/DTA criteria for the TPSCS plans and Shapiro-Wilk test p-values.
ΔD/DTA
Criteria
5%/1mm
3%/3mm
3%/2mm
3%/1mm
2%/2mm
2%/1mm
1%/1mm

C4 (%)

T1 (%)

T12 (%)

L2 (%)

L4 (%)

97.57 ± 0.52
99.62 ± 0.05
98.13 ± 0.62
90.53 ± 2.68
95.95 ± 0.56
85.68 ± 3.78
79.00 ± 2.76

96.03 ± 1.03
98.80 ± 0.39
97.23 ± 1.45
88.10 ± 1.67
94.41 ± 1.70
78.24 ± 2.12
67.96 ± 3.52

98.13 ± 2.64
98.33 ± 2.76
97.03 ± 4.56
89.74 ± 10.70
92.87 ± 7.89
78.99 ± 13.63
65.52 ± 11.14

99.65 ± 0.13
99.61 ± 0.19
98.61 ± 0.30
91.49 ± 3.28
95.72 ± 0.71
80.01 ± 3.73
66.50 ± 2.22

98.33 ± 2.52
97.82 ± 3.22
96.56 ± 4.93
87.89 ± 10.27
93.90 ± 7.81
76.70 ± 13.53
64.08 ± 13.53

Mean GPR ± σ
across sites (%)
97.94 ± 1.31
98.84 ± 0.79
97.51 ± 0.84
89.55 ± 1.55
94.57 ± 1.29
79.93 ± 3.44
68.61 ± 5.98

Shapiro-Wilk p-value
0.889
0.439
0.699
0.548
0.651
0.250
0.047

Table 3.15. GPR ± σ at multiple ΔD/DTA criteria for the TPSMC plans and Shapiro-Wilk test p-values.
ΔD/DTA
Criteria
5%/1mm
3%/3mm
3%/2mm
3%/1mm
2%/2mm
2%/1mm
1%/1mm

C4 (%)

T1 (%)

T12 (%)

L2 (%)

L4 (%)

95.87 ± 2.29
98.32 ± 0.43
95.48 ± 1.00
87.60 ± 4.04
93.60 ± 1.20
81.56 ± 4.84
74.51 ± 4.88

90.90 ± 1.74
93.30 ± 1.27
89.16 ± 1.03
75.82 ± 2.35
85.26 ± 0.91
65.84 ± 2.29
57.45 ± 2.18

96.03 ± 2.56
98.00 ± 1.57
94.98 ± 3.17
87.43 ± 5.39
91.35 ± 3.94
77.89 ± 6.63
66.17 ± 7.34

93.71 ± 2.62
94.83 ± 2.76
90.09 ± 4.31
79.55 ± 8.00
84.86 ± 6.69
67.61 ± 9.72
55.55 ± 8.70

94.57 ± 1.28
95.44 ± 2.05
90.25 ± 3.19
79.83 ± 5.72
82.39 ± 6.34
65.80 ± 11.07
50.15 ± 12.22

Mean GPR ± σ
across sites (%)
94.22 ± 2.09
95.98 ± 2.14
91.99 ± 2.99
82.04 ± 5.24
87.49 ± 4.74
71.74 ± 7.44
60.77 ± 9.61

Shapiro-Wilk p-value
0.347
0.509
0.097
0.239
0.422
0.096
0.760

Table 3.16. Mean GPR ± σ across the treatment sites at multiple ΔD/DTA criteria for TPSCS and TPSMC.
ΔD/DTA
Criteria
5%/1mm
3%/3mm
3%/2mm
3%/1mm
2%/2mm
2%/1mm
1%/1mm

TPSCS Mean GPR ± σ across sites (%)

TPSMC Mean GPR ± σ across sites (%)

Levene p-value

T-test p-value

97.94 ± 1.31
98.84 ± 0.79
97.51 ± 0.84
89.55 ± 1.55
94.57 ± 1.29
79.93 ± 3.44
68.61 ± 5.98

94.22 ± 2.09
95.98 ± 2.14
91.99 ± 2.99
82.04 ± 5.24
87.49 ± 4.74
71.74 ± 7.44
60.77 ± 9.61

0.371
0.031
0.001
0.008
0.005
0.018
0.210

0.010
0.038
0.012
0.030
0.027
0.070
0.160
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3.5. Uncertainty
Three main sources of measurement uncertainty were independently documented: The
inherent profile shift, the registration standard deviation, and the imaging-radiation isocenter
coincidence.
The inherent profile shift for the film was determined by planning a simple 6 MV 4-field
box plan in TPSCS with the flattening filter included (4 beams: Anterior-Posterior, PosteriorAnterior, Right-Left, and Left-Right). This plan was dubbed 'RegTestFF.' Following the same film
dosimetry procedure as the spine plans, AP and LAT profiles were obtained through the center of
dose distribution (Figure B.42 through Figure B.44). The TPSCS profile compared with three trials
of film profiles for this plan yielded an average -0.1 ± 0.3 mm AP profile shift at the 1250 cGy
dose point (negative signifying an anterior shift). If this shift is accounted for in each site's average
profile shift, that is, add +0.1 mm to each, the TPSCS and TPSMC mean profile shifts across all sites
become +0.0 mm and +0.1 mm, respectively. These values remain smaller than the dose plane
resolution, suggesting high accuracy between the planned and measured film profiles.
The RegTestFF film AP and LAT dose profiles also exhibited an average of 61.74 cGy
underestimation (-3.9% relative to Rx) compared to the TPSCS profiles. This dose difference was
not specifically seen in the spine plans' film measurements, however. Most film dose profiles were
higher inside the PTV compared to their TPS profile.
The registration standard deviation between the TPS dose plane and each film scan was
outputted by the film analysis software, shown in Table 3.17 below. The software's technical
manual recommends the standard deviation be less than the inverse of the 'Reference' image's
resolution (1 mm in this case).32 For each treatment site, all standard deviations met this
requirement. The T1 site's standard deviation was the highest, which may explain its high mean
profile shift (Table 3.12). Regardless, the registration for all trials appeared very accurate.
Table 3.17. Registration standard deviation for each film measurement trial (A, B, and C) and the
trial average for each site.
Treatment Site

C4

T1

T12

Trial
A
B
C
AVG
A
B
C
AVG
A
B
C
AVG

TPSCS Registration
Standard Deviation (mm)
0.143
0.141
0.154
0.146
0.873
0.843
0.877
0.864
0.278
0.346
0.292
0.305

(table cont'd.)
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TPSMC Registration
Standard Deviation (mm)
0.166
0.136
0.117
0.140
0.894
0.874
0.841
0.870
0.292
0.313
0.308
0.304

Treatment Site

L2

L4

RegTestFF
(4-field Box Plan)

Trial
A
B
C
AVG
A
B
C
AVG
A
B
C
AVG

TPSCS Registration
Standard Deviation (mm)
0.158
0.194
0.163
0.172
0.189
0.198
0.169
0.185
0.147
0.209
0.216
0.191

TPSMC Registration
Standard Deviation (mm)
0.173
0.148
0.163
0.161
0.199
0.242
0.194
0.212
-

The imaging-radiation isocenter coincidence was determined by examining the linac's daily
Winston-Lutz planar images of a cubic phantom (MIMI, REF 91240, Standard Imaging, Inc.,
Middleton, Wisconsin) taken as part of the linac's daily QA procedure. The selected images were
acquired on the same day of each spinal treatment delivery (or previous day for Saturday
measurements). The center of a BB in the imaged QA phantom (imaging isocenter) and the center
of the MLC window (radiation isocenter) were estimated, then the distance between them was
measured. The distances measured between the isocenters were averaged across the spine
treatment days, yielding the values in Table 3.18 below. The SI and AP distances were measured
on the Left-Right planar images to avoid the extra offset caused by the gantry's forward sag. The
lateral (LAT) distances were measured with the AP planar image. If the AP isocenter coincidence
is accounted for in each treatment site's average profile shift, that is, add +0.2 mm to each, the
TPSCS and TPSMC mean profile shifts across all sites become +0.1 mm and +0.2 mm, respectively.
Again, these values remain below the dose plane's resolution, implying highly accurate
measurements within the linac's tolerance. Note that these shifts in Table 3.18 are limited to a 0.25
mm image resolution.
Table 3.18. Imaging isocenter shifts relative to the radiation isocenter for each day of film
measurement. Positive values indicate a shift in the superior, anterior, or left direction. Negative
values indicate a shift in the inferior, posterior, or right direction.
Treatment (Site-TPSTrial)
C4-CSA,B
T1-CSA,B,C
C4-CSC, T1-MCA,B,C
C4-MCA,B,C, T12-CSA,B,C
T12-MCA,B,C
L2-CSA,B,C
L2-MCA,B,C
L4-CSA,B,C, L4-MCA,B,C
RegTestFF (4-Field Box Plan)

Date
09/02/2021
09/13/2021
09/21/2021
10/16/2021
10/19/2021
10/26/2021
10/27/2021
10/30/2021
12/11/2021
Mean Shift

SI Shift (mm)
0.00
0.00
-1.25
+0.25
0.00
0.00
+0.25
0.00
-0.50
-0.1 ± 0.5
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AP Shift (mm)
0.00
+0.25
+0.25
+0.25
+0.50
+0.50
+0.25
-0.25
0.00
+0.2 ± 0.2

LAT Shift (mm)
0.00
-0.25
-0.75
0.00
-0.25
0.00
-0.25
0.00
+1.00
-0.1 ± 0.5

Chapter 4. Discussion and Conclusion
4.1. Validation Plan Summary
In the TG-119 validation plans, TPSMC was, on average, slightly more accurate than TPSCS,
in terms of point dose measurements and average GPR. It is possible that a thinner slice thickness
would have produced more accurate low dose measurements in the Multitarget plan since they
involved SI shifts of the water slabs. The Cshape plan experienced many 'Terminated Fault' linac
errors during treatment delivery (for both TPSs), which stopped the treatment and usually required
readjustment of the gantry angle before continuing. These interruptions occasionally occurred
during the C4 and T12 spine plan deliveries as well. The high degree of plan modulation may be
the cause of this and could explain why the Cshape plan had the highest dose differences compared
to the other validation plans.
With these thoughts in mind and considering the very high GPR for the validation plans,
the newly commissioned 6 MV FFF beam model in TPSMC appeared to be accurate enough for
research purposes. It should also be noted that the task group report's institutional results were
based on plans that used seven or nine IMRT fields with the flattening filter in place, rather than
FFF VMAT fields.
4.2. Spine Film Profiles and GPR Summary
In the critical region between the PTV and cord/cauda, both planning systems, on average,
calculated the dose gradient with no significant difference in accuracy in terms of dose falloff and
profile shift. The dose points in this region tended to pass the gamma analyses very well, but
usually failed when the DTA reached 1 mm, (excluding 5%/1mm criteria). These specific results
do not support the hypothesis of this work. The higher GPRs from the TPSCS spine plans compared
to those from TPSMC, were surprising, given the fact that MC-based dose calculation algorithms
are generally considered more accurate than CS-based.3, 11, 38
The TPSMC spine plans used many more MU, and thus were more modulated than the
TPSCS spine plans (Table 3.1). The lower GPRs seen on the film measurements of the TPSMC spine
plans suggest that the resulting high modulation pushed the linac to its mechanical limits.39 At
some instances during the TPSMC plan deliveries, all except for one row of MLCs were blocked
by the linac jaws. The following settings specific to TPSMC may have contributed to the lower
GPR: the minimum segment width, maximum leaf travel per gantry rotation, and maximum
number of control points.
The minimum segment width in TPSMC was set to 0.5 cm, as recommended by one of the
vendor training manuals.24 The corresponding setting in TPSCS, minimum dynamic leaf gap, was
1 cm. Wang et al. found that re-planning in TPSMC with a minimum segment width of either 1.0
or 1.5 cm resulted in an increased GPR and a decreased total number of MU generated per plan
compared with a 0.5 cm minimum segment width.40 A study by Saenz et al. comparing plans
calculated and optimized in the TPSs used in this work also found that TPSMC generated more MU
than TPSCS.15 Saenz et al. also used a 0.5 cm minimum segment width in TPSMC. Conversely, a
study by Lee et al. found that TPSCS generated more MU than TPSMC,14 but minimum segment
width used was not disclosed. Both these studies used higher prescriptions doses, though (20 Gy
in one fraction and 24 Gy in 2 fractions, respectively), and neither one confirmed their plans with
ion chamber or film measurements.
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Limiting the MLC movement speed (in mm per degree of gantry rotation) has been shown
by Yang et al. to increase GPR while reducing the number of MU in TPSCS.41 The leaves were
limited to 4.6 mm per degree in our TPSCS spine plans, but in TPSMC, this setting was left blank
by default.
The VMAT control point spacing (degrees) is determined in TPSMC automatically during
segmentation, increasing the number of control points at gantry angles where high modulation is
required and decreasing the number at angles where less modulation is needed.24 The result is
varied control point spacing at each segment in TPSMC. This cannot be manually changed, as
opposed to TPSCS, where the control point spacing is a single user-entered value. Reducing the
maximum number of control points allowed in TPSMC, however, may slightly reduce the total MU
delivered as it does for TPSCS, decreasing plan modulation.41 Determining the effect of plan
modulation on plan deliverability by examining relationships between these three TPSMC settings
and the resulting measurements may be pursued in a future study.
One possible explanation for the lower GPR inside the PTVs of TPSMC specifically is the
auto-filling of the hollow ring contours when importing the structures from TPSCS. While the
shrink margin feature in TPSMC was used to create optimization goals for each plan, the imported
ring structures were used to measure the volume outside the CTV that the 105% dose hotspots
occupied. If this volume exceeded 2 cc, the plan was optimized further to reduce the hotspot
volume, following RTOG 0631.21 Mistakenly, the filled portions of the ring structures were not
noticed and corrected until after all film measurements and analyses were completed. This meant
that the hotspot volume measurements included portions of the PTV volumes. RTOG 0631 does
not prohibit dose inhomogeneity or hotspots inside the target,21 so relying on the incorrect ring
structure volumes possibly caused TPSMC to limit the hotspots more than necessary. This could be
why the internal PTV of the vertebral sites in TPSMC had colder dose distributions than TPSCS.
The push for colder doses combined with the TPS settings described previously may have
contributed to the higher plan modulation and lower GPR inside the PTVs. However, this would
only explain the decreased GPR in the T12, L2, and L4 sites, as the C4 and T1 sites' ring contours
were only filled near the superior and inferior edges of the targets.
A study by Haga et al. involved planning treatments at a variety of anatomical sites in
TPSCS, then transferring the optimized VMAT segments to TPSMC. TPS-calculated point doses
were then compared with ion chamber measurements in a water phantom and cork phantom.13
Directly importing the control points enables detection of dose differences between each TPS
independent of the differences between optimization methods and TPS-specific settings.
Performing anthropomorphic phantom film measurements of plans in each TPS with identical
beam data as Haga did is another potential avenue of future study.
4.3. Limitations
Although both TPSCS and TPSMC used identical CT images and structure sets, the TPScalculated volumes of the structures slightly differed between the two. The contours for the spine
plans were created in TPSCS in 'Poly' mode, which displays the contours at the edge of the CT
voxels. When the structures were imported to TPSMC, the structures were shifted to the center of
the CT voxels, which created 1 mm gaps between some contours in TPSMC where they previously
were adjacent in TPSCS. This caused the structures in TPSMC to have slightly smaller defined
volumes compared to those in TPSCS, though it is difficult to determine whether this would produce
a significant dosimetric effect in the planning results.
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Another difference between TPSCS and TPSMC is how the CT number to density tables are
defined. In TPSCS, it is defined in terms of physical density vs. Hounsfield units + 1000, but in
TPSMC, it is defined in terms of electron density relative to water (RED) vs. Hounsfield units.
TPSMC converts the RED values to physical density using analytical equations.25 However, the
vendor recommends that, for non-human media such as tissue equivalent material, the RED values
be adjusted in order to produce a physical density that matches its actual value instead of solely
relying on the conversion equations. This was not performed when commissioning TPSMC. A test
spine SBRT plan was calculated on a previously treated patient in TPSMC using both a CT number
to density table with nominal RED values and one with adjusted RED values. The highest observed
mean dose difference between the two tables relative to 1600 cGy was 1.1% at the vertebra's
posterior edge (data not shown). This is smaller than the systematic dose underestimation of the
film observed in the RegTestFF plan (see the Uncertainty subsection in Results), so compared to
the settings discussed previously, it is not likely a crucial source of dose differences between each
TPS.
When analyzing the film measurements, some sources of uncertainty were not considered.
The calibration films were arranged in three rows while scanned (Figure 2.6), with the central row
approximately aligned with the scanner's central axis (parallel to the scan direction). It is possible
that the calibration films in the outer rows experienced some lateral response artifact, in which the
measured PV decreases laterally (perpendicular from the scan direction) from the scanner central
axis.29, 42–45 The film analysis software used in this project does not currently offer a method to
correct for this artifact. If it were corrected on the scanned image of the calibration films, the
measured PV of the lateral calibration film patches would increase slightly, ultimately increasing
the dose of the whole calibration curve. In the film measurements of the spine plans, however, this
artifact was not visibly seen. This is likely because of the relatively small lateral size of the
vertebral treatment targets. The largest vertebral site was L4, about 5.2 cm across. The lateral
response artifact also would have no effect on the AP dose profiles since each film's AP axis was
aligned perpendicular to the scan direction and approximately centered near the scanner axis. This
artifact is currently being characterized for our institution's scanner for Gafchromic EBT3 film as
part of another graduate student's project.
The film analysis software was also limited to reading either the PV of one color channel
or simply measuring the mean of all three channels. Some studies suggest a number of triplechannel dosimetry methods that can improve film measurement accuracy. 46, 47 Such methods are
currently not available in the software used, and time-constraints prevented the hand-coding of it.
4.4. Conclusion
The end-to-end accuracy of single-fraction spine SBRT plans at several vertebral sites in a
CS-based TPS and MC-based TPS were evaluated with radiochromic film measurements. On
average, each TPS calculated the dose profiles between the vertebral bodies and spinal cord within
1 mm accuracy. Gamma analyses in this specific region showed good agreement with the
calculated doses for all ΔD/DTA criteria tested, except for 3%/1mm, 2%/1mm, and 1%/1mm
sometimes. The lower GPR throughout other areas in the TPSMC sites, specifically at 2%/2mm
criteria, may be improved by placing appropriate optimization limits that reflect the capabilities of
the linac used in the treatments. Specific settings identified in this work were minimum segment
width, maximum leaf travel per gantry rotation, and maximum number of control points.
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Appendix A. Spine Treatment Planning Methodology
The overall inverse planning philosophy in each TPS was to attempt to meet the PTV dose
coverage while limiting OAR dose and reducing dose hotspots outside of the CTV to the limits
specified in ROTG 0631.21
All DICOM structures (CTVs, PTV, OARs, etc.) in the phantom were contoured in TPSCS.
After contouring the CTV and PTV structures of each site (named [Site]_CTV and
[Site]_2mm_PTV in the TPS, respectively), two ring structures were created. Each ring was a 1
cm expansion the CTV and PTV, named [Site]_Ring1_1cm_PTV and [Site]_Ring1_1cm_CTV,
respectively. The rings were expanded in all directions, but settings were specified to avoid the
spinal cord structure (named [Site]_PartCord0.25mm_contract) and cauda equina structure (Figure
A.1). Either one ring or both rings were used as an objective during inverse optimization for each
site to control the maximum dose around each vertebral body. TPSCS has a Scorecard feature that
quickly calculates doses to individual structures and compares them with user-entered dosimetric
criteria. Both rings were included in the Scorecard in order to evaluate the dose hotspot volume up
to 1 cm outside the CTV as well as the maximum dose outside the CTV and PTV.

Figure A.1. The L4 site in TPSCS with L4_CTV contoured in red, L4_2mm_PTV in orange,
Cauda Equina in green, and L4_Ring1_1cm_PTV shaded in purple.
In addition, structures named [Site]_Cold_Post were made to cover some site's pedicles
and portions of the internal posterior CTV to improve target coverage. Irregularly-shaped
structures named [Site]_Limit Back were placed a few centimeters posterior to the cord / cauda to
decrease circumferential dose around them. Both the Cold_Post and Limit Back contours were
occasionally edited throughout the optimization in attempts to shift some isodose lines.
The inverse planning objectives were revised and adjusted as needed throughout the
planning process. The last used criteria for the plans in TPSCS are shown in Table A.1 through
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Table A.5. The objective value for each row gives a measure of how close the dose goal was to
being met. A lower value implies that the dose goal was met and signals the optimization algorithm
to focus on meeting other goals. The weight parameter may be manually adjusted on some
objectives to increase the objective value, which in turn increases the optimization algorithm's
focus on that goal. The composite objective value is the sum of all objective values.
Table A.1. Final IMRT optimization objectives for the C4 plan in TPS CS.
Structure
C4_2mm_PTV
C4_Cold_Post
C4_Limit Back
C4_PartCord0.25mm_contract
C4_Ring1_1cm_PTV
Skin
Trachea & Larynx

Type
Max Dose
Min DVH
Min Dose
Min Dose
Max DVH
Max DVH
Max Dose
Max Dose
Max Dose
Max DVH
Max Dose

Target Dose
Volume
Weight
(cGy)
(%)
1720
97
5
1680
5
1520
5
1480
1
500
20
1
940
9
4
1340
2
1480
3
2300
1
1050
24
1
2020
1
Composite Objective Value

Objective Value
7.44088e-05
0.00122388
0.000204882
0
0
0.000109722
4.44104e-06
0.00165311
0
0
0
0.00327045

Table A.2. Final IMRT optimization objectives for the T1 plan in TPSCS.
Structure
BrachPlex close
Esophagus
Lung_Tot
Skin
T1_2mm_PTV
T1_Cold_Post
T1_Limit Back
T1_PartCord0.25mm_contract
T1_Ring1_1cm_CTV
T1_Ring1_1cm_PTV

Type
Max DVH
Max Dose
Max DVH
Max Dose
Max DVH
Max Dose
Max Dose
Min DVH
Min Dose
Min Dose
Max DVH
Max DVH
Max Dose
Max Dose
Max Dose

Target Dose
Volume
Weight
(cGy)
(%)
1400
50
1
1750
1
1190
20
1
1460
1
740
20
1
2300
1
1720
6
1680
97
8
1520
8
1480
5
950
10
1
920
9
8
1250
8
1650
5
1480
5
Composite Objective Value
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Objective Value
0
0
0
6.85621e-06
0
0
0.000128042
0.00345028
0.000936043
0.000960953
0.000195212
0.00018757
3.88076e-05
0.000103189
0.0010349
0.00704185

Table A.3. Final IMRT optimization objectives for the T12 plan in TPSCS.
Structure
Duodenum
Lung_Tot
Renal Cortex L & R
Renal Hilum L & R
Skin
Stomach
T12_2mm_PTV
T12_Cold Post
T12_Limit Back
T12_PartCord0.25mm_contract
T12_Ring1_1cm_CTV
T12_Ring1_1cm_PTV

Type
Max DVH
Max Dose
Max DVH
Max Dose
Max DVH
Max Dose
Max DVH
Max Dose
Max Dose
Min DVH
Min Dose
Min Dose
Max DVH
Max DVH
Max Dose
Max Dose
Max Dose

Target Dose
Volume
Weight
(cGy)
(%)
1120
7
1
1600
1
740
21
1
840
1
1060
66
1
2300
1
1120
15
1
1600
1
1740
5
1680
97
5
1540
5
1520
1
900
10
1
960
9
8
1300
8
1650
1
1480
1
Composite Objective Value

Objective Value
0
0
0
3.34729e-11
0
0
0
0
3.20092e-06
0.00171851
0.000985871
0.000418885
0
0.00018884
2.48648e-07
1.96845e-05
0.00043729
0.00377253

Table A.4. Final IMRT optimization objectives for the L2 plan in TPSCS.
Structure
Cauda Equina
Duodenum
L2_Cold Post
L2_Limit Back
L2_PartCord0.25mm_contract
L2_Ring1_1cm_CTV
L2_2mm_PTV
Renal Cortex L & R
Renal Hilum L & R
Stomach

Type
Max DVH
Max Dose
Max DVH
Max Dose
Min Dose
Max DVH
Max DVH
Max Dose
Max Dose
Max Dose
Min DVH
Min Dose
Min DVH
Max Dose
Max DVH
Max DVH
Max Dose

Target Dose
Volume
Weight
(cGy)
(%)
1000
7
1
1300
1
1120
7
1
1600
1
1520
4
900
10
1
960
9
1
1400
1
1440
1
1760
5
1680
97
5
1540
5
1600
90
4
840
1
1060
66
1
1120
10
1
1600
1
Composite Objective Value

43

Objective Value
4.54262e-05
0.000137597
0
0
3.38985e-05
0
2.38277e-05
0
0.00343336
1.20001e-06
0.00173833
0.00020188
0
0
0
0
0
0.00561551

Table A.5. Final IMRT optimization objectives for the L4 plan in TPSCS.
Structure
Cauda Equina
Duodenum
L4_Cold Post
L4_Limit Back
L4_Ring1_1cm_PTV
L4_2mm_PTV
Renal Cortex L & R
Renal Hilum L & R

Type
Max DVH
Max Dose
Max DVH
Max Dose
Min Dose
Max DVH
Max Dose
Max Dose
Min DVH
Min Dose
Max Dose
Max DVH

Target Dose
Volume
Weight
(cGy)
(%)
1350
20
1
1500
1
1120
7
1
1600
1
1560
2
900
10
1
1440
1
1760
5
1680
98
5
1560
5
840
1
1060
66
1
Composite Objective Value

Objective Value
0
1.06784e-05
0
0
7.96038e-07
0
0.000391367
0
0.00168039
8.1144e-05
0
0
0.00216437

When all the contoured structures were imported from TPSCS to TPSMC, the system
automatically filled the hollow areas of ring-shaped contours, i.e., donut shaped contours became
filled circles. This increased the volume of the Ring contours. Similar to the Scorecard feature in
TPSCS, TPSMC displays user-customizable dosimetric criteria. This dosimetric criteria was checked
during the plan optimization to confirm adequate target coverage, OAR sparing, and dose hotspot
limits 1 cm outside of the CTV. However, because the Ring structures included the interior of the
vertebral body in some slices, the hotspot volumes were overestimated. The plans in TPSMC were
mistakenly chosen to be optimized further, unnecessarily decreasing overall dose inside the target.
The filled Ring structures were noticed months after the plan delivery and data analysis. They were
corrected by manually trimming the Rings from the PTV and CTV and allowing a thin hollow
channel to extend from the inner to outer border of each Ring, as shown in Figure A.2. These
corrections allowed the true values for the hotspot volumes outside of the CTV and the maximum
point doses outside of the CTV and PTV to be recorded in Table 3.1.

Figure A.2. L4_Ring1_1cm_PTV shaded in purple in TPSMC upon direct import from TPSCS
(Left). L4_Ring1_1cm_PTV in TPSMC after manually correcting the contour (Right). Note the
small opening directly posterior to the green cauda equina structure which prevents the ring from
being filled.
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As in TPSCS, the optimization criteria in the TPSMC plans were adjusted throughout the
inverse planning process. 'Constrained' optimization was used as opposed to 'Pareto' to prioritize
OAR dose constraints over target coverage. The last used criteria for each TPSMC plan are
displayed in Table A.6 through Table A.10. The 'cost functions' are analogous to the dose goals in
Table A.1 through Table A.5, but the significance of the reference dose and 'isoconstraint' values
depends on the cost function used.
'Target Penalty' is analogous to 'Minimum DVH,' with the isoconstraint representing the
minimum dose desired for a user-specified minimum volume (%) of coverage (shown in the table
caption). 'Quadratic Overdose' is similar to a 'Max Dose' constraint, with its reference dose
representing the maximum dose, and the isoconstraint representing the root mean square dose
excess, a user-entered dose value that allows the structure to exceed the reference dose by a small
amount. 'Overdose DVH' acts similarly to 'Max DVH,' with its reference dose representing the
objective dose and the isoconstraint representing the maximum volume (%) of the structure the
dose will occupy. 'Maximum Dose' is a hard physical dose limit, and its isoconstraint is simply the
maximum allowed dose in the structure. 'Conformality' pushes high dose areas to the target area,
increasing conformity as its isoconstraint is lowered.24
The weights in TPSMC were automatically adjusted by the system, as opposed to the
weights in TPSCS, which were manually adjusted. The shrink margin feature in TPSMC essentially
mimics the Ring structures from TPSCS. For example, in Table A.6, there are three shrink margins
for the structure 'External ROI with Rods.' This structure contains the entire phantom contour and
the frame rods. Without the shrink margins, the optimizer would attempt to meet the dose goal
(1680.0 cGy) in every location inside the phantom except for the interior of the PTV. With the
shrink margins enabled as shown, the optimizer attempted to limit the dose to 1680.0 cGy
immediately outside of the PTV, 1520.0 cGy 2 mm away from the PTV, and 1440.0 cGy 4 mm
away from the PTV and beyond.
Table A.6. Final IMRT optimization objectives for the C4 plan in TPSMC. The target penalty
minimum volume for C4_2mm_PTV is 96%.
Structure
BrachPlex close
C4_2mm_PTV
C4_PartCord0.25cm_contract
External ROI with Rods

Cost Function

Weight

Overdose DVH
Target Penalty
Quadratic Overdose
Maximum Dose
Maximum Dose
Overdose DVH
Conformality
Quadratic Overdose
Quadratic Overdose
Quadratic Overdose

0.01
1.00
0.01
2.23
0.03
7.65
0.02
0.01
0.01
0.01
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Reference Dose
(cGy)
1400.0
1740.0
1000.0
1680.0
1520.0
1440.0

Shrink Margin
(cm)
0.00
0.00
0.00
0.20
0.40

Isoconstraint
30.00
1640.0
40.0
1800.0
1380.0
9.50
0.63
40.0
40.0
40.0

Table A.7. Final IMRT optimization objectives for the T1 plan in TPSMC. The target penalty
minimum volume for T1_2mm_PTV is 96%.
Structure
Esophagus
BrachPlex close
T1_2mm_PTV
T1_PartCord0.25cm_contract
External ROI with Rods

Cost Function

Weight

Maximum Dose
Overdose DVH
Overdose DVH
Target Penalty
Quadratic Overdose
Maximum Dose
Maximum Dose
Overdose DVH
Conformality
Quadratic Overdose
Quadratic Overdose
Quadratic Overdose

0.16
0.01
1.33
1.00
0.01
2.42
0.01
12.37
0.01
0.01
0.01
0.01

Reference Dose
(cGy)
1190.0
1400.0
1740.0
1000.0
1680.0
1520.0
1440.0

Shrink Margin
(cm)
0.00
0.00
0.00
0.20
0.40

Isoconstraint
1580.0
15.00
40.00
1640.0
40.0
1780.0
1380.0
9.50
0.63
40.0
40.0
40.0

Table A.8. Final IMRT optimization objectives for the T12 plan in TPSMC. The target penalty
minimum volume for T12_2mm_PTV is 96%.
Structure
T12_2mm_PTV
T12_PartCord0.25cm_contract
External ROI with Rods

Cost Function

Weight

Target Penalty
Quadratic Overdose
Maximum Dose
Maximum Dose
Overdose DVH
Conformality
Quadratic Overdose
Quadratic Overdose
Quadratic Overdose

1.00
0.01
1.28
0.01
24.21
0.01
0.01
0.01
0.01

Reference Dose
(cGy)
1720.0
1000.0
1660.0
1500.0
1420.0

Shrink Margin
(cm)
0.00
0.00
0.00
0.20
0.40

Isoconstraint
1680.0
40.0
1800.0
1380.0
9.00
0.60
40.0
40.0
40.0

Table A.9. Final IMRT optimization objectives for the L2 plan in TPSMC. The target penalty
minimum volume for L2_2mm_PTV is 95%.
Structure
L2_2mm_PTV
L2_PartCord0.25cm_contract
Cauda Equina
External ROI with Rods

Cost Function

Weight

Target Penalty
Quadratic Overdose
Maximum Dose
Maximum Dose
Overdose DVH
Maximum Dose
Overdose DVH
Conformality
Quadratic Overdose
Quadratic Overdose
Quadratic Overdose

1.00
0.01
0.62
0.01
0.99
0.28
0.01
0.01
0.01
0.01
0.01
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Reference Dose
(cGy)
1740.0
1000.0
1400.0
1660.0
1500.0
1420.0

Shrink Margin
(cm)
0.00
0.00
0.00
0.00
0.00
0.20
0.40

Isoconstraint
1640.0
40.0
1780.0
1380.0
9.50
1580.0
25.00
0.60
40.0
40.0
40.0

Table A.10. Final IMRT optimization objectives for the L4 plan in TPSMC. The target penalty
minimum volume for L4_2mm_PTV is 96%.
Structure
L4_2mm_PTV
SacrPlex close
Cauda Equina
External ROI with Rods

Cost Function

Weight

Target Penalty
Quadratic Overdose
Maximum Dose
Overdose DVH
Maximum Dose
Overdose DVH
Conformality
Quadratic Overdose
Quadratic Overdose
Quadratic Overdose

1.00
0.01
1.22
0.06
1.64
0.01
0.01
0.01
0.01
0.01

47

Reference Dose
(cGy)
1720.0
1420.0
1440.0
1660.0
1500.0
1420.0

Shrink Margin
(cm)
0.00
0.00
0.00
0.00
0.20
0.40

Isoconstraint
1660.0
40.0
1780.0
30.00
1570.0
20.00
0.60
40.0
40.0
40.0

Appendix B. Full Dose Profile Results
Table B.1 and Table B.2 display the AP dose falloffs of the TPSCS-calculated profiles, each individual trial (A, B, and C) of filmmeasured AP profiles, and the differences and percent differences between the TPS and film. Table B.3 and Table B.4 display the same
for the TPSMC-calculated profiles. Table B.5 and Table B.6 display the AP profile shift between each TPS and film for each trial.
Figure B.1 through Figure B.40 display all planned dose distributions with the red AP profile marked followed by plots of the
planned AP profile and the measured AP profile of each trial. For the cervical and thoracic profile, the shaded region represents the area
between the posterior contour edge of the PTV and anterior contour edge of the spinal cord. For the lumbar profiles, the PTV contour
edge and cauda equina contour edge were directly adjacent. Figure B.41 through Figure B.47 show the same for the three RegTestFF
trials in TPSCS, including planned and measured AP and LAT profiles.
Table B.1. AP dose falloff, dose falloff difference and percent dose falloff difference for each trial (A, B, and C), and average (AVG)
value ± σ for the TPSCS cervical and thoracic sites.
Treatment Site

C4

Trial

T1

T12

A

B

C

AVG

A

B

C

AVG

A

B

C

AVG

TPSCS Dose Falloff (mm)

8.9

8.9

8.9

8.9

8.6

8.6

8.6

8.6

7.2

7.2

7.2

7.2

Film Dose Falloff (mm)

9.2

8.3

8.4

8.6 ± 0.5

9.6

8.8

9.2

9.2 ± 0.4

6.4

7.9

6.6

7.0 ± 0.8

Difference (mm)

+0.3

-0.6

-0.5

-0.3 ± 0.5

+1.0

+0.2

+0.6

+0.6 ± 0.4

-0.8

+0.7

-0.6

-0.3 ± 0.8

Difference (%)

+3.6

-6.8

-5.6

-2.9 ± 5.7

+11.8

+2.4

+7.1

+7.1 ± 4.7

-10.9

+9.4

-9.0

-3.5 ± 11.2

Table B.2. AP dose falloff, dose falloff difference and percent dose falloff difference for each trial (A, B, and C), and average (AVG)
value ± σ for the TPSCS lumbar sites.
Treatment Site
Trial

L2

L4

A

B

C

AVG

A

B

C

AVG

TPSCS Dose Falloff (mm)

7.9

7.9

7.9

7.9

13.7

13.7

13.7

13.7

Film Dose Falloff (mm)

8.3

9.0

8.8

8.7 ± 0.4

13.3

13.1

11.6

12.7 ± 1.0

Difference (mm)

+0.4

+1.1

+1.0

+0.8 ± 0.4

-0.4

-0.6

-2.2

-1.1 ± 1.0

Difference (%)

+5.5

+14.3

+12.3

+10.7 ± 4.7

-3.1

-4.4

-15.9

-7.8 ± 7.1
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Table B.3. AP dose falloff, dose falloff difference and percent dose falloff difference for each trial (A, B, and C), and average (AVG)
value ± σ for the TPSMC cervical and thoracic sites.
Treatment Site

C4

Trial

T1

T12

A

B

C

AVG

A

B

C

AVG

A

B

C

AVG

TPSMC Dose Falloff (mm)

8.2

8.2

8.2

8.2

9.8

9.8

9.8

9.8

9.2

9.2

9.2

9.2

Film Dose Falloff (mm)

7.9

7.6

8.0

7.8 ± 0.2

10.1

9.5

9.5

9.7 ± 0.3

9.0

8.3

8.8

8.7 ± 0.3

Difference (mm)

-0.3

-0.7

-0.3

-0.4 ± 0.2

+0.2

-0.3

-0.3

-0.1 ± 0.3

-0.2

-0.9

-0.4

-0.5 ± 0.3

Difference (%)

-3.6

-8.3

-3.3

-5.1 ± 2.8

+2.4

-2.8

-3.5

-1.3 ± 3.2

-2.4

-9.3

-3.9

-5.2 ± 3.6

Table B.4. AP dose falloff, dose falloff difference and percent dose falloff difference for each trial (A, B, and C), and average (AVG)
value ± σ for the TPSMC lumbar sites.
Treatment Site

L2

Trial

L4

A

B

C

AVG

A

B

C

AVG

TPSMC Dose Falloff (mm)

6.9

6.9

6.9

6.9

9.0

9.0

9.0

9.0

Film Dose Falloff (mm)

6.2

6.3

6.0

6.2 ± 0.1

6.4

8.2

7.8

7.5 ± 1.0

-0.8

-0.6

-0.9

-0.8 ± 0.1

-2.6

-0.7

-1.2

-1.5 ± 1.0

-11.3

-9.0

-12.8

-11.0 ± 1.9

-28.7

-8.3

-13.0

-16.6 ± 10.7

Difference (mm)
Difference (%)

Table B.5. AP profile shift for each trial (A, B, and C) and average (AVG) value ± σ for the cervical and thoracic sites.
Treatment Site

C4

Trial

T1

T12

A

B

C

AVG

A

B

C

AVG

A

B

C

AVG

TPSCS Profile shift (mm)

+0.2

+0.2

+0.1

+0.2 ± 0.1

-0.7

-0.6

-0.4

-0.6 ± 0.2

-0.3

-0.2

-0.2

-0.3 ± 0.1

TPSMC Profile shift (mm)

-0.1

-0.4

-0.3

-0.3 ± 0.1

-0.9

-0.9

-0.9

-0.9 ± 0.0

+0.2

+0.4

+0.7

+0.4 ± 0.2

Table B.6. AP profile shift for each trial (A, B, and C) and average (AVG) value ± σ for the lumbar sites.
Treatment Site
Trial

L2

L4

A

B

C

AVG

A

B

C

AVG

TPSCS Profile shift (mm)

+0.0

-0.3

-0.4

-0.2 ± 0.2

+0.1

-0.1

+0.8

+0.3 ± 0.5

TPSMC Profile shift (mm)

+0.1

+0.2

+0.2

+0.2 ± 0.1

+0.8

+1.1

+0.4

+0.7 ± 0.3
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Figure B.1. AP dose profile over the TPSCS C4 planned dose distribution.

Figure B.2. Planned AP TPSCS dose profile with its respective film-measured dose profile for the
C4 site, trial A.
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Figure B.3. Planned AP TPSCS dose profile with its respective film-measured dose profile for the
C4 site, trial B.

Figure B.4. Planned AP TPSCS dose profile with its respective film-measured dose profile for the
C4 site, trial C.
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Figure B.5. AP dose profile over the TPSMC C4 planned dose distribution.

Figure B.6. Planned AP TPSMC dose profile with its respective film-measured dose profile for
the C4 site, trial A.
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Figure B.7. Planned AP TPSMC dose profile with its respective film-measured dose profile for
the C4 site, trial B.

Figure B.8. Planned AP TPSMC dose profile with its respective film-measured dose profile for
the C4 site, trial C.
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Figure B.9. AP dose profile over the TPSCS T1 planned dose distribution.

Figure B.10. Planned AP TPSCS dose profile with its respective film-measured dose profile for
the T1 site, trial A.
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Figure B.11. Planned AP TPSCS dose profile with its respective film-measured dose profile for
the T1 site, trial B.

Figure B.12. Planned AP TPSCS dose profile with its respective film-measured dose profile for
the T1 site, trial C.
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Figure B.13. AP dose profile over the TPSMC T1 planned dose distribution.

Figure B.14. Planned AP TPSMC dose profile with its respective film-measured dose profile for
the T1 site, trial A.
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Figure B.15. Planned AP TPSMC dose profile with its respective film-measured dose profile for
the T1 site, trial B.

Figure B.16. Planned AP TPSMC dose profile with its respective film-measured dose profile for
the T1 site, trial C.
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Figure B.17. AP dose profile over the TPSCS T12 planned dose distribution.

Figure B.18. Planned AP TPSCS dose profile with its respective film-measured dose profile for
the T12 site, trial A.
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Figure B.19. Planned AP TPSCS dose profile with its respective film-measured dose profile for
the T12 site, trial B.

Figure B.20. Planned AP TPSCS dose profile with its respective film-measured dose profile for
the T12 site, trial C.
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Figure B.21. AP dose profile over the TPSMC T12 planned dose distribution.

Figure B.22. Planned AP TPSMC dose profile with its respective film-measured dose profile for
the T12 site, trial A.
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Figure B.23. Planned AP TPSMC dose profile with its respective film-measured dose profile for
the T12 site, trial B.

Figure B.24. Planned AP TPSMC dose profile with its respective film-measured dose profile for
the T12 site, trial C.
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Figure B.25. AP dose profile over the TPSCS L2 planned dose distribution.

Figure B.26. Planned AP TPSCS dose profile with its respective film-measured dose profile for
the L2 site, trial A.

62

Figure B.27. Planned AP TPSCS dose profile with its respective film-measured dose profile for
the L2 site, trial B.

Figure B.28. Planned AP TPSCS dose profile with its respective film-measured dose profile for
the L2 site, trial C.
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Figure B.29. AP dose profile over the TPSMC L2 planned dose distribution.

Figure B.30. Planned AP TPSMC dose profile with its respective film-measured dose profile for
the L2 site, trial A.
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Figure B.31. Planned AP TPSMC dose profile with its respective film-measured dose profile for
the L2 site, trial B.

Figure B.32. Planned AP TPSMC dose profile with its respective film-measured dose profile for
the L2 site, trial C.
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Figure B.33. AP dose profile over the TPSCS L4 planned dose distribution.

Figure B.34. Planned AP TPSCS dose profile with its respective film-measured dose profile for
the L4 site, trial A.
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Figure B.35. Planned AP TPSCS dose profile with its respective film-measured dose profile for
the L4 site, trial B.

Figure B.36. Planned AP TPSCS dose profile with its respective film-measured dose profile for
the L4 site, trial C.

67

Figure B.37. AP dose profile over the TPSMC L4 planned dose distribution.

Figure B.38. Planned AP TPSMC dose profile with its respective film-measured dose profile for
the L4 site, trial A.
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Figure B.39. Planned AP TPSMC dose profile with its respective film-measured dose profile for
the L4 site, trial B.

Figure B.40. Planned AP TPSMC dose profile with its respective film-measured dose profile for
the L4 site, trial C.
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Figure B.41. AP and LAT dose profiles over the TPSCS 4-field box (RegTestFF) planned dose
distribution.

Figure B.42. Planned AP TPSCS dose profile with its respective film-measured dose profile for
RegTestFF, trial A.
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Figure B.43. Planned AP TPSCS dose profile with its respective film-measured dose profile for
RegTestFF, trial B.

Figure B.44. Planned AP TPSCS dose profile with its respective film-measured dose profile for
RegTestFF, trial C.
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Figure B.45. Planned LAT TPSCS dose profile with its respective film-measured dose profile for
RegTestFF, trial A.

Figure B.46. Planned LAT TPSCS dose profile with its respective film-measured dose profile for
RegTestFF, trial B.
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Figure B.47. Planned LAT TPSCS dose profile with its respective film-measured dose profile for
RegTestFF, trial C.
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Appendix C. Full Gamma Analysis Results
Table C.1 through Table C.4 display the GPR of each individual trial (A, B, and C) for all treatments sites from each TPS. Figure
C.1 through Figure C.15 show the film-measured dose distribution of each trial in both TPSCS and TPSMC. The red pixels have a gamma
calculated greater than 1, failing the 2%/2mm ΔD/DTA criteria. Figure C.16 through Figure C.19 show the same for the TG-119
validation plans.
Table C.1. GPR of each trial (A, B, and C) and average (AVG) GPR ± σ for the TPSCS cervical and thoracic sites.
Site

C4

T1

T12

Trial

A

B

C

AVG

A

B

C

AVG

A

B

C

AVG

5%/1mm

98.09

97.56

97.06

97.57 ± 0.52

97.12

95.08

95.90

96.03 ± 1.03

99.75

99.56

95.08

98.13 ± 2.64

3%/3mm

99.57

99.67

99.63

99.62 ± 0.05

98.95

98.36

99.10

98.80 ± 0.39

99.96

99.89

95.15

98.33 ± 2.76

3%/2mm

98.80

97.99

97.59

98.13 ± 0.62

97.94

95.56

98.19

97.23 ± 1.45

99.66

99.67

91.76

97.03 ± 4.56

3%/1mm

90.40

87.92

93.28

90.53 ± 2.68

88.72

86.21

89.37

88.10 ± 1.67

97.51

94.17

77.54

89.74 ± 10.70

2%/2mm

96.59

95.58

95.68

95.95 ± 0.56

95.65

92.48

95.11

94.41 ± 1.70

97.04

97.79

83.77

92.87 ± 7.89

2%/1mm

85.55

81.97

89.53

85.68 ± 3.78

76.26

77.98

80.47

78.24 ± 2.12

87.38

86.33

63.27

78.99 ± 13.63

1%/1mm

78.92

76.28

81.80

79.00 ± 2.76

64.25

68.37

71.25

67.96 ± 3.52

70.21

73.55

52.81

65.52 ± 11.14

2

ROI (cm )

6×4.84

6×5.71

8×6.78

Table C.2. GPR of each trial (A, B, and C) and average (AVG) GPR ± σ for the TPSCS lumbar sites.
Site

L2

L4

Trial

A

B

C

AVG

A

B

C

AVG

5%/1mm

99.53

99.78

99.64

99.65 ± 0.13

99.58

99.97

95.43

98.33 ± 2.52

3%/3mm

99.40

99.66

99.78

99.61 ± 0.19

99.68

99.68

94.10

97.82 ± 3.22

3%/2mm

98.33

98.57

98.93

98.61 ± 0.30

99.54

99.27

90.87

96.56 ± 4.93

3%/1mm

88.10

91.74

94.64

91.49 ± 3.28

92.19

95.32

76.17

87.89 ± 10.27

2%/2mm

95.85

94.96

96.36

95.72 ± 0.71

98.44

98.38

84.88

93.90 ± 7.81

2%/1mm

77.50

78.24

84.29

80.01 ± 3.73

82.99

85.95

61.17

76.70 ± 13.53

1%/1mm

66.50

64.28

68.71

66.50 ± 2.22

70.02

73.63

48.60

64.08 ± 13.53

2

ROI (cm )

8×6.88

8×7.17
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Table C.3. GPR of each trial (A, B, and C) and average (AVG) GPR ± σ for the TPSMC cervical and thoracic sites.
Site

C4

T1

T12

Trial

A

B

C

AVG

A

B

C

AVG

A

B

C

AVG

5%/1mm

97.51

93.25

96.85

95.87 ± 2.29

88.94

92.25

91.50

90.90 ± 1.74

98.53

96.15

93.42

96.03 ± 2.56

3%/3mm

98.66

97.84

98.46

98.32 ± 0.43

92.28

94.72

92.91

93.30 ± 1.27

99.39

98.32

96.30

98.00 ± 1.57

3%/2mm

96.20

94.33

95.90

95.48 ± 1.00

88.05

90.08

89.36

89.16 ± 1.03

97.92

95.40

91.63

94.98 ± 3.17

3%/1mm

92.13

84.36

86.30

87.60 ± 4.04

73.58

75.60

78.27

75.82 ± 2.35

93.34

86.15

82.79

87.43 ± 5.39

2%/2mm

94.79

92.39

93.61

93.60 ± 1.20

84.58

86.30

84.91

85.26 ± 0.91

94.92

92.00

87.12

91.35 ± 3.94

2%/1mm

87.02

77.79

79.87

81.56 ± 4.84

64.10

64.99

68.44

65.84 ± 2.29

85.22

76.15

72.30

77.89 ± 6.63

1%/1mm

80.13

71.34

72.07

74.51 ± 4.88

55.74

56.71

59.91

57.45 ± 2.18

73.86

65.41

59.24

66.17 ± 7.34

2

ROI (cm )

6×4.84

6×5.71

8×6.79

Table C.4. GPR of each trial (A, B, and C) and average (AVG) GPR ± σ for the TPSMC lumbar sites.
Site

L2

L4

Trial

A

B

C

AVG

A

B

C

AVG

5%/1mm

91.08

96.31

93.74

93.71 ± 2.62

93.24

94.67

95.79

94.57 ± 1.28

3%/3mm

95.01

97.50

91.98

94.83 ± 2.76

93.10

96.31

96.92

95.44 ± 2.05

3%/2mm

89.40

94.71

86.17

90.09 ± 4.31

86.66

92.73

91.37

90.25 ± 3.19

3%/1mm

74.76

88.78

75.10

79.55 ± 8.00

75.33

86.27

77.88

79.83 ± 5.72

2%/2mm

84.37

91.78

78.43

84.86 ± 6.69
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Figure C.1. C4-TPSCS-A (Left) and C4-TPSMC-A (Right) dose points failing gamma criteria
2%/2mm.

Figure C.2. C4-TPSCS-B (Left) and C4-TPSMC-B (Right) dose points failing gamma criteria
2%/2mm.

Figure C.3. C4-TPSCS-C (Left) and C4-TPSMC-C (Right) dose points failing gamma criteria
2%/2mm.
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Figure C.4. T1-TPSCS-A (Left) and T1-TPSMC-A (Right) dose points failing gamma criteria
2%/2mm.

Figure C.5. T1-TPSCS-B (Left) and T1-TPSMC-B (Right) dose points failing gamma criteria
2%/2mm.

Figure C.6. T1-TPSCS-C (Left) and T1-TPSMC-C (Right) dose points failing gamma criteria
2%/2mm.
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Figure C.7. T12-TPSCS-A (Left) and T12-TPSMC-A (Right) dose points failing gamma criteria
2%/2mm.

Figure C.8. T12-TPSCS-B (Left) and T12-TPSMC-B (Right) dose points failing gamma criteria
2%/2mm.

Figure C.9. T12-TPSCS-C (Left) and T12-TPSMC-C (Right) dose points failing gamma criteria
2%/2mm.
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Figure C.10. L2-TPSCS-A (Left) and L2-TPSMC-A (Right) dose points failing gamma criteria
2%/2mm.

Figure C.11. L2-TPSCS-B (Left) and L2-TPSMC-B (Right) dose points failing gamma criteria
2%/2mm.

Figure C.12. L2-TPSCS-C (Left) and L2-TPSMC-C (Right) dose points failing gamma criteria
2%/2mm.
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Figure C.13. L4-TPSCS-A (Left) and L4-TPSMC-A (Right) dose points failing gamma criteria
2%/2mm.

Figure C.14. L4-TPSCS-B (Left) and L4-TPSMC-B (Right) dose points failing gamma criteria
2%/2mm.

Figure C.15. L4-TPSCS-C (Left) and L4-TPSMC-C (Right) dose points failing gamma criteria
2%/2mm.
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Figure C.16. TG-119 Multitarget site diode array measurements failing (red) gamma criteria
2%/2mm in TPSCS (Left) and TPSMC (Right).

Figure C.17. TG-119 Prostate site diode array measurements failing (red) gamma criteria
2%/2mm in TPSCS (Left) and TPSMC (Right).
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Figure C.18. TG-119 Head/Neck site diode array measurements failing (red) gamma criteria
2%/2mm in TPSCS (Left) and TPSMC (Right).

Figure C.19. TG-119 Cshape site diode array measurements failing (red) gamma criteria
2%/2mm in TPSCS (Left) and TPSMC (Right).
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